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Abstract
Background. Native arteriovenous fistula (AVF) is the vascular access of
choice and its use c.f. catheters is associated with sustained reduction in
mortality. This may be due to factors beyond dialysis catheter associated
sepsis. This study aims to investigate the impact of AVF formation on the
spectrum of cardiovascular factors that might be important in the
pathophysiology of cardiovascular diseases in CKD patients.
Methods. We recruited 43 pre-dialysis patients who underwent AVF
formation. Patients were studied two weeks prior to AVF operation, two
weeks and three months postoperatively. Haemodynamic variables were
measured using pulse wave analysis, carotid femoral pulse wave velocity
(CF-PWV) by applanation tonometry and AVF blood flow by Doppler
ultrasound. Bioimpedence analysis was performed and patients underwent
serial transthoracic echocardiography. Laser Doppler Perfusion Imaging and
iontophoresis were used to assess endothelial dependant (ED) and non-
endothelial dependant (NED) vasodilatation.
Results. AVF formation was successful in 30/43 patients. Two weeks
postoperatively, total peripheral resistance decreased (-17 18%, p=0.001),
stroke volume tended to rise (12 30ml, p=0.053) and both heart rate (4
8bpm, p=0.01) and cardiac output (1.1 1.5l/min, p=0.001) increased. Systolic
and diastolic blood pressures reduced (-9 18mmHg; -9 10mmHg; ≤ p=0.006).
CF-PWV reduced (-1.1 1.5m/sec, p=0.004). Left ventricular ejection fraction
(LVEF) increased (6 8%, p<0.001). Patients with successful AVF formation
xii
had a significantly reduced ED vasodilatation in the fistula arm -36±46%,
p<0.001. Only NED vasodilatation was significantly reduced in the non-fistula
arm 23±40%, p=0.01. Patients who had  unsuccessful AVF operation
exhibited no recordable changes.
All the observed haemodynamic changes were largely maintained after 3
months. No change in hydration status/body composition was observed.
AVF formation resulted in a sustained reduction in arterial stiffness and BP as
well as an increase in LVEF. Furthermore, there were significant changes in
the local and systemic microcirculation. Overall, post AVF adaptations might
be characterised as potentially beneficial in these patients and supports the
widespread use of native vascular access, including older or cardiovascular
compromised individuals.
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Introduction
21 Introduction
1.1 Chronic Kidney Disease
1.1.1 Scope of the problem
Chronic Kidney Disease (CKD) is a major public health problem worldwide
with increasing incidence and prevalence. World Health Report 2002 and
Global Burden of Disease project pointed out that diseases of the kidney and
urinary tract contribute to the global burden of diseases, with approximately
850,000 deaths every year and 15,010,167 disability-adjusted life years. They
are the 12th cause of death and the 17th cause of disability respectively1. A
survey of blood samples carried out in the South East of England in 2000/01
found the prevalence of diagnosed CKD to be 5,554 per million population
with 84.4% of these patients were unknown to renal services2. A systemic
review into 26 population based studies reported that the median prevalence
of CKD was 7.2% in persons aged 30 years or older and in persons aged 64
years or older prevalence of CKD varied from 23.4% to 35.8%3.
Associated with this increase in prevalence, is the disproportionate
consumption of health care resources. The total coast of care for ESRD
patients in the US was around $22.7 billion in 20064.
31.1.2 Definition and staging
CKD is defined as the presence of objective kidney damage and/or the
presence of glomerular filtration rate of 60 ml/min/1.73m2 body surface area
or less for at least 3 months, irrespective of the underlying aetiology of the
kidney damage.
Detection, early initiation of effective therapy and investigation into the
epidemiology of CKD was limited by the lack of a uniform terminology. The
guidelines proposed from the National Kidney Foundation of the United
States through its Kidney Disease Outcomes Quality Initiative (KDOQI)
program were introduced to achieve this goal5. These guidelines are accepted
internationally and they provide a necessary foundation to help to standardize
the current medical practice.
The KDOQI working group defined chronic kidney disease in adults as:
? Kidney damage for ≥3 months, as defined by structural or functional
abnormalities of the kidney, with or without decreased GFR, manifest by
either:
1. Pathological abnormalities, or
2. Markers of kidney damage, including abnormalities in the
composition of blood, urine or imaging tests.
OR
? Decreased GFR, with or without evidence of kidney damage.
4CKD is further subdivided into 5 subgroups according to the degree of
severity of eGFR reduction
Table 1.1 Stages of Chronic Kidney Diseases (CKD)
GFR (mL/min/1.73 m2) Stages Description
≥90 1
Kidney damage with
normal or ↑GFR
60-89 2
Kidney damage with
mild ↓GFR
30-59 3 Moderate ↓GFR
15-29 4 Severe ↓GFR
< 15 5
End Stage Renal
Disease (ESRD)
51.2 Cardiovascular Diseases in patients with CKD
Cardiovascular diseases (CVD) are the leading cause of mortality and
morbidity in patients with CKD. CKD patients are more likely to die from a
CVD than developing kidney failure6-7. This increased risk begins in earlier
stages of CKD before the onset of renal failure. Patients with CKD not only
have a very high prevalence of more conventional cardiovascular risk factors
such as diabetes and hypertension but also they are exposed to the
complications of the kidney failure such as uraemia related CVD and
complications associated with the treatment of the renal failure.
It has been shown in multiple studies that there is evidence of CVD in early
stages of CKD.  In a cross sectional study, it has been shown that there was
a gradual increase in the number of patients who had left ventricular
hypertrophy (LVH) as renal function declined with the largest prevalence
(45%) when creatinine clearance dropped below 25mL/min8. This in contrast
to the 20% prevalence of LVH in general population of similar age9.
It is very well known that patients with CKD have a higher prevalence and
incidence of CVD such as ischemic heart diseases and heart failure10-11. They
are also at higher risk of death after an acute myocardial infarction12-13. This is
very clearly shown in several epidemiological studies looking into morbidity
and mortality in patients with CKD. In the Cardiovascular Health Study,
patients with CKD, had heart failure (8%), IHD (26%) and 55% had
hypertension.  This was in contrast to patients without CKD 13% had heart
failure, 3% had IHD and 36% had hypertension. Furthermore, it was shown
6that patients with CKD had CVD event rate of 102 per 1000 patient year. This
in contrast to subjects without CKD who had CVD event rate of only 44 per
1000 patient year14. Further more, the risk of cardiovascular events increases
as GFR declines and this has been clearly demonstrated in Atherosclerosis
Risk in Communities (ARIC) study which showed that the level of GFR is an
independent risk factor for atherosclerotic cardiovascular disease in subjects
aged 45 to 64 years.
Figure1.1 Smoothed five-year predicted probability of developing atherosclerotic
cardiovascular disease by level of glomerular filtration rate (GFR).
7Amongst ESRD patients who are on dialysis, CVD is the leading cause of
mortality, accounting for up to 45% of deaths15. This is also been shown by
epidemiological studies reporting increase CV mortality by 10% to 30% in
dialysis patients compared to general population16.
Figure 1.2 Cardiovascular disease mortality by age, race, and gender in the general
population and in dialysis patients.
81.3 Risk Factors for CVD in CKD patients
In addition to the traditional risk factors associated with CVD, there are
several non-traditional factors which play important role in the pathogenesis
and outcome of CVD in CKD patients as shown in the table below.
Table 1.2 Risk factors for cardiovascular diseases in patients with CKD.
Traditional risk factors Non-traditional risk factors
Hypertension
Diabetes
Smoking
Dyslipidaemia
Left ventricular hypertrophy
Inactive life style
Male
Age
Menopause
Family history
Homocysteinemia
Albuminuria
Abnormal calcium/phosphate
metabolism
Fluid overload
Oxidative stress
Inflammation (C-reactive protein)
Malnutrition
Thromobogenic factors
Altered nitric oxide/endothelin balance
Anaemia
Vascular calcification
Elevated lipoprotein A
Increased asymmetrical dimethyl-
arginine(ADMA)
91.3.1 Traditional CVD risk factors
Blood pressure
As well as being considered an exacerbating factor in CKD, hypertension is
one of the major complications in CKD patients. Although the prevalence of
hypertension widely varies depending on the nature of the underlying cause
of CKD, it increases almost linearly as kidney function falls. Up to 80-90% of
patients with different stages of CKD have hypertension17.
The mechanisms which can contribute to high blood pressure in CKD patients
include expansion of the extracellular volume, increased activity of the renin-
angiotensine-aldosterone system, abnormal endothelial cell function,
abnormal parathyroid hormone level and iatrogenic factors such as
erythropoietin stimulating agent administration.
In patients with ESRD on dialysis, hypertension has been associated with
adverse CV outcome and it is an independent risk factor for IHD, left
ventricular hypertrophy, heart failure and stroke18 and the overall CV mortality
in CKD patients19.  It has been shown that cardiovascular mortality increased
by 2.93 folds in patients with uncontrolled hypertension prior to starting
dialysis20. In ESRD patients, a mean pre dialysis blood pressure of >98
mmHg was associated with 2.2 fold increase in CV death compared to those
with mean blood pressure of <98 mmHg21. Controlling hypertension is of
paramount importance in slowing the progression of CKD and reducing CV
risks in this group of patients22.
10
It is important to note that relationship between blood pressure and CV
morbidity and mortality in dialysis patients is a complex one. Low blood
pressure may indicate heart failure/cardiomyopathy and it predisposes
patients to increased episodes of intradialytic hypotension which is associated
with increased mortality23. In dialysis patients, it has been demonstrated that
each 10 mmHg increase in the mean arterial pressure was independently
associated with progressive increase in concentric left ventricular hypertrophy
and the development of denovo heart failure and ischaemic heart diseases18.
Paradoxically, the same study showed that lower blood pressure levels were
associated with significantly increased mortality,
Diabetes Mellitus
Diabetes is the most common cause of CKD and it account for over 40% of
ESRD patients on dialysis. It is generally accepted that 25-40% of patients
with either type 1 or 2 diabetes will develop diabetic nephropathy.
The earliest manifestation of diabetic nephropathy is microalbuminuria (>30
mg/24 hours), but recent studies have shown this pattern is changing with
patients presenting with increased creatinine and normal urinary albumin
levels.
Microalbuminuria on its own is a very significant risk factor for the progression
of CKD and the development of other CV diseases24-25.
11
Although patients with CKD have significantly higher CV morbidity and
mortality compared to general population, the subgroup of CKD patients with
diabetes have even increased incidence of peripheral vascular disease,
microvascular diseases and  ischaemic heart disease. Diabetes is an
independent risk factor for IHD, heart failure and all cause mortality in dialysis
patients26. It has been shown that presence of both diabetes and CKD
together increases mortality rate in patients undergoing invasive cardiac
investigation and treatment compared to those with CKD patients but without
diabetes27.
Figure 1.3 Freedom from all cause mortality for patients with CK and diabetes
12
Left ventricular hypertrophy (LVH)
LVH is a physiological adaptation to a long term increase in myocardial
workload. It can happen secondary to increased pressure and/or volume
overload. In addition to the conventional factors causing LVH in general
population, other factors contributing to LVH in CKD population include
increased arterial stiffness, uncontrolled hypertension, increased extracellular
volume, anaemia, and presence of AVF.
Pressure overload requires increased intracavity pressure to overcome the
increased afterload during systole. This results in hypertrophy. This in turn
causes increased myocardial workload and may precipitate myocardial
ischaemia in absence of significant coronary artery disease. In addition,
volume overload leads to addition of new sacromeres which in longer term
results in hypertrophy. This again causes reduction in subendocardial
perfusion and subsequent myocardial fibrosis. Eventually, this can end up in
dilated cardiomyopathy and systolic dysfunction28.
In epidemiological studies, LVH is present in up to 50% of CKD pre-dialysis
patients and this increases to around 75% in patients on dialysis. There is a
negative correlation between LVH on one hand and reduced glomerular
filtration rate (GFR), reduced haemoglobin and higher systolic blood pressure
on the other hand. LVH is well know to be an independent risk factor for CV
morbidity and mortality in dialysis patients29-31.
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Dyslipidaemia
As well as being a risk factor for CVD in CKD population, dyslipidaemia may
be a mediator of CKD progression. CKD is associated with profound lipid
dysregulation which is different to dylipidaemia in general population. Plasma
triglyceride (TGL) concentration is frequently elevated but plasma cholesterol
level is usually normal, even reduced or rarely mildly elevated in CKD. The
increased level of TGL is associated with high concentration and impaired
clearance of very low density lipoprotein (VLDL). There is a similar elevation
in plasma chylomicron level due to impaired clearance. Plasma concentration
of low density lipoprotein (LDL) is normal and only mildly elevated in CKD.
High density lipoprotein concentration is almost always reduced inpatients
with CKD.
Due to this unusual form of dyslipidaemia, it has been reported that the
relationship between cholesterol level and mortality in CKD patients is more
complex than general population. Low cholesterol levels were associated with
increased mortality in dialysis patients32-34 . It is believed that increased all
cause and cardiovascular mortality in dialysis patients with low cholesterol is
due to the association between hypocholestrolaemia and increased
inflammation/malnutrition34.
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1.3.2 Non traditional CVD risk factors
Homocysteinemia
Homocysteine (Hcy) levels increase as GFR declines due to reduced
clearance of Hyc. Hyperhomocystienaemia is much more common in dialysis
patients and it is believed that up to 80% of patients in ESRD have elvated
level of Hcy. Higher level of Hcy has been implicated as a risk factor for
myocardial infarction and stroke in ESRD patients. Few  studies have shown
that homocysteinemia is an independent risk factor for CVD mortality in
dialysis patients35.
Not all studies have shown that hyperhomocyteinaemia to be an independent
risk factor for CV diseases in dialysis patients. Furthermore, Hyc levels has
been associated with nutritional status and in subjects with nutritional
deficiencies, low Hcy levels are associated with a worst outcome37, therefore
nutritional status, albumin level and presence of other co-morbidities should
be taken into consideration when evaluating Hcy level as a risk factor for CV
diseases in CKD patients.
Lowering Hcy levels has not been constantly associated with a favourable
outcome. Indeed, a more recent trial demonstrated that lowering
homocystiene levels with a combination of folic acid, vitamin B6 and B12 did
not reduce the risk of major cardiovascular events in patients with vascular
diseases36.
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Inflammation and Oxidative stress
Renal failure causes changes in plasma components and endothelial
structure and function that favour vascular injury, which may play a role as a
trigger for Inflammatory response38-40. Up to 50% of CKD patients have
elevated serum levels of inflammatory markers such as C-reactive protein,
fibrinogen, interleukin-6, and tumor necrosis factor41-44.
Mechanisms are unclear but increased inflammatory mediators have been
attributed to increased oxidative stress, advanced glycation end products
(AGE), and other agents normally cleared by the kidney.
The mechanisms causing increased oxidative stress in CKD is not completely
understood. Increased production of radical oxygen species combined with
reduced clearance in addition to an impaired antioxidant defence system
might all contribute. Additionally, CKD usually coexists with other diseases
(diabetes and hypertension) that are known to be causing oxidative stress.
Several mechanisms have been proposed as the cause of oxidative stress in
uraemia. These include activation of reduced nicotinamide adenine
dinucleotide oxidase, xanthine oxidase and myeloperoxidase 40 45.
Kidney plays an important role in the clearance of AGE. There is a growing
body of evidence suggesting that increased levels of AGE is associated with
an increase in the proinflammatory and oxidative stress status, endothelial
dysfunction46-47 and arterial stiffness.48-49
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Endothelial Dysfunction, Nitric Oxide bioavailability, and Asymmetric
dimethyl arginine (ADMA)
Endothelial dysfunction is recognised as one of the initial mechanisms that
lead to atherosclerosis. Endothelial dysfunction, which occurs in both large
and small arteries, is present in renal disease50. Microalbuminuria, a marker
of glomerular hyperfiltration, has been correlated with and may be a
manifestation of impaired endothelial function51.
Reduced bioavailability of nitric oxide (NO) appears to be one of the main
factors involved in chronic renal failure ?associated endothelial dysfunction.
ADMA is a competitive inhibitor of NO synthase and has been implicated as
the potential link between endothelial dysfunction and CVD in CKD. ADMA is
primarily cleared by the kidneys and it accumulates in renal impairment. In
vitro, ADMA inhibits NO generation, and in humans it reduces forearm blood
flow and cardiac output and increases systemic vascular resistance and blood
pressure52.
Plasma concentrations of ADMA are increased in association with endothelial
dysfunction and/or reduced NO production, particularly in renal failure53.
Elevated plasma concentrations of ADMA are associated not only with
endothelial dysfunction and atherosclerosis54 but predict mortality and CV
complications in CKD and end stage renal failure55.
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Arterial stiffness
There is an increasing awareness that abnormal large artery function plays an
important role in the pathogenesis of CVD. Arterial walls alter their structure
and function in response to atherogenic and atherosclerotic factors, as well as
changes in the haemodynamic burden. As a result, the structural changes
can include activation and proliferation of smooth muscle cells and
rearrangement of cellular elements and extracellular matrix of the vessel
wall56. This disruption of the architecture with the increase of collagen and
loss of elastic fibres results in a reduction in arterial compliance and an
increase in arterial stiffness.
Increased arterial stiffness, with an associated increase in the amplitudes of
the forward and reflected pressure waves, is a major determinant of
increased systolic and pulse pressure with advancing age. Increased pulse
pressure and aortic augmentation index, as indirect measures of arterial
stiffness, and carotid-femoral pulse wave velocity (CF-PWV), a more direct
measure of stiffness, are associated with adverse clinical events.
Pressure wave reflection serves two beneficial purposes. When normally
timed, the reflected wave returns to aorta in diastole and therefore enhances
diastolic perfusion pressure in the coronary circulation. Partial wave reflection
also returns a portion of the pulsatile energy content of the wave form to the
central aorta where it is dissipated by viscous damping. Thus, wave reflection
limits transmission of pulsatile energy into the periphery where it might
otherwise damage the microcirculation. Thus the loss of this protective
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function of wave reflection could contribute to the pathogenesis of a growing
spectrum of cardiovascular and non cardiovascular complications.
It has been shown that there is a positive association between GFR and
arterial stiffness57. It was also demonstrated that there is a step wise increase
in arterial stiffness as CKD stages progresses from stage1 to stage5 58.
It has also been demonstrated that aortic pulse wave velocity and arterial
wave reflections predict the extent and severity of coronary artery disease in
chronic kidney disease patients59.
In addition to being a likely consequence of CKD, increased aortic stiffness
determined by measurement of aortic PWV was shown to be a strong
independent predictor of all-cause and mainly cardiovascular mortality in
dialysis patients60(see figure 1.4). Furthermore, same study demonstrated
that an increase in the PWV by 1 m/s resulted in an increase in the all cause
mortality adjusted odd ratio by 1.39.
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Figure 1.4  A)overall and B)cardiovascular mortality according
 to PWV divided into tertiles
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1.4 Haemodialysis access
Maintaining a functional haemodialysis (HD) access is one of the important
challenges nephrologists face today.  Vascular access failure is associated
with significant morbidity and fistula dysfunction is the most common reason
for recurrent hospitalisation and need for secondary intervention 61. This
however represents only the tip of the iceberg.  Vascular access
complications account for 16 ?25% of hospital admissions in dialysis patients
and depending on the type of vascular access in use, is correlated with
overall and cause-specific mortality 62. There is significant cost associated
with vascular access failure; 8000 US dollars per patient at risk per year in the
United States, ~15% of Medicare ?s expenditure for end-stage renal disease
63.  Thus, long term functioning of vascular access is of crucial importance in
haemodialysis patients.
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1.5 Arteriovenous fistula for haemodialysis
1.5.1 Definition
An AVF is a surgically placed shunt whereby an artery (a high pressure
vessel) is anastomosed to a vein (low pressure vessel), forming a high flow
low resistance system allowing blood flow from the artery to the vein.
As flowing blood seeks the path of least resistance, the fistula acts effectively
as a short-circuit between the arterial circulation and the venous circulation.
Over time the created fistula matures; opening the fistula reducing peripheral
resistance and dramatically increases flow through the proximal artery 64. To
accommodate the increased volume of blood flow through the fistula, without
increasing the shear wall stress excessively, there is usually a widening of the
fistula circuit.  As the fistula matures, the proximal vein becomes more
prominent, more thick walled and it is this that facilitates successful, repetitive
percutaneous venepuncture for haemodialysis.
Blood flowing through a fistula is determined by the sum of flow resistance of
the arterial system, the anastomosis itself and the flow resistance of the
venous system.  Blood flow will be in the direction of high to low pressure,
therefore flow in all arterial limbs will be towards the anastamosis and in
venous limbs away from the anastomosis.
Adequate fistula maturation, i.e. sufficient dilatation and arterialisation, is a
prerequisite for repeated cannulation for haemodialysis treatment 65.  Factors
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such as age, sex, blood pressure and associated illnesses are likely involved
in AVF maturation 66-67.
1.5.2 History of haemodialysis/ AVF development
Dialysis was first described by Thomas Graham in 1854. He described
separating substances through a semi-permeable membrane68. While a
significant amount of research was conducted into artificial membranes
between 1880-1913, it wasn ?t until 1914 Abel et al. tested the first efficient
dialysis system at Johns Hopkins University School of Medicine69. The first
human haemodialysis was performed in a uraemic patient by Haas in 1924 at
the University of Giessen in Germany70.  To obtain access, he used a glass
cannula to cannulate radial artery and returned the blood to cubital vein.
Initially he used hirudin for anticoagulation which was replaced later with
heparin due to side effects.
This was followed by significant improvement in dialysers and membrane
designs in 1940 ?s and 50 ?s. Although haemodialysis technology continued to
develop, the technique of obtaining access did not evolve equally alongside.
The cannulation technique was proving to be even less effective and was
prone to complications.  In 1960 the first external AV shunt was invented by
Scribner and colleagues, using a rigid Teflon tube held over a stainless steel
plate with each end cannulating an artery and vein respectively. They were
more successful in providing long term intermittent haemodialysis sessions
than previous methods.  Previous publications quoted mean arterial cannula
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survival of 7.8 months and mean venous cannula survival of 7.2 months71.
Complications associated with these shunts included clotting, bleeding,
infection of the cutaneous cannula and subsequent systemic sepsis.
It was not until the surgeons Cimino and Brescia in 1966 created the first
subcutaneous shunt by performing a side to side anastomosis between radial
artery and cephalic vein72.  The current AVF is still based on the same design
with one modification.  Currently an end vein to side artery anastomosis is
more in practice as it is associated with fewer complications than the original
Cimino fistula.
1.5.3 Types of Vascular access
1.5.3.1 Arteriovenous Fistula
Why Native AVF is the best dialysis access?
Native AVF is the vascular access of first choice73. The most recent and
valuable data is obtained from Dialysis Outcomes and Practice Patterns
Study (DOPPS) which is a prospective cohort study of haemodialysis
practices based on the collection of observational longitudinal data for a
random sample of patients from dialysis units in 12 countries. It concluded
that when used as a patient's first access, AVF survival was superior to grafts
regarding time to first failure. It is well known from clinical practice that AVF
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have longer periods of usefulness, higher flow rates and lower associated
complication rates in comparison to other forms of access.
Recent guidelines published by the American National Kidney Foundation-
Kidney Disease Outcomes Quality Initiative (KDOQI) recommend that at least
50% of new haemodialysis patients have a primary AVF, leading to better
patency rates and lower access-related costs 74. The use of definitive
vascular access in HD patients, rather than tunnelled central venous
catheters, is associated with sustained reduction in mortality over at least
three years75. AVF has been proven repeatedly to have the lowest risk of
infection and thrombosis compared to other forms of access.
Anatomical locations
Autogenous upper arm AVF can be created in arm or forearm. The usual
practice is to start as distally as possible in the non dominant arm and move
proximally. Doppler ultrasound has been used in vascular mapping for
assessing anatomical (diameter) and physiological (flow rate) parameters of
the blood vessels preoperatively. The exclusion criteria are widely variable
between different centres; however; generally speaking a vein diameter of
less than 2.5-3 mm and abnormal arterial flow pattern or reduced flow are
contraindications for AVF formation. The first anatomic location to be initially
considered for anastomosis is radial artery-cephalic vein. Other less
commonly used anastomosis are radial artery-basilic vein and ulnar artery-
basilic vein. However, these are more technically challenging to construct,
needling requires much more skill and it is less comfortable for the patient to
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stay in a specific posture for the duration of the dialysis treatment. In upper
arm, brachocephalic AVF is most commonly used as it is more straightforward
to construct. Brachiobasilic AVF formation is more challenging for the surgeon
as it requires dissection and mobilisation of basilic vein to make it more
superficial for future needling. However, recent studies have shown
barchiobasilic AVF to have better outcomes and its use are becoming more
popular76.
Disadvantages of AVF
Although AVF formation is universally the choice of vascular access for all the
reasons previously discussed, there are disadvantages.  Firstly, AVF is
required to undergo a maturation process of 2-3 months.  An AVF may fail to
mature (failure of outflow vein to enlarge sufficiently to allow for repeated
cannulation), resulting in the need for a catheter to initiate dialysis. A non
functional AVF is defined as the inability to use the AVF for 2- needle
haemodialysis within 8 weeks of surgery 65. It is recognised that AVF fail to
mature in at least one third of cases 77.  Failure of maturation can be
attributed to inadequate arterial inflow, outflow vein stenosis, poor surgical
anastomosis and development of collateral veins that delay maturation by
siphoning flow 78. The fistula should be examined approximately 4 weeks
after creation and referred for imaging and correction of identified lesions if
not maturing by 6 weeks. Most non-maturing fistulae have identifiable lesions
that can be corrected by percutaneous techniques. In a series of 100 AV
fistulae with early failure, 78% had a venous stenosis, 38% anastomotic
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stenosis and 46% accessory veins diverting blood and preventing adequate
maturation. After percutaneous treatment, 92% became usable for
hemodialysis and 84% remained functional at 3 months, 72% at 6 months
and 68% at 12 months79.
For AVF s that thrombose within few days to weeks of their creation, salvage
is not usually attempted due to low success rates.
Complications of AVF
AVF can dilate and become aneurysmal due to damage and weakening in the
wall following repeated cannulation. Pseudoaneurysm may form following
extravasation of blood after dialysis. These carry the risk of rupture and fistula
failure.
AVF can also be complicated by thrombosis, infection and haemorrhage.
Thrombosis is a leading cause of vascular access failure and is the outcome
of stenosis caused by progressive neointimal hyperplasia in the venous
outflow system 80.
Dialysis associated steal syndrome is also a recognised complication of
fistula formation. This is more common in patients with vascular diseases,
diabetes and in elderly patients. It is defined as a clinical condition caused by
arterial insufficiency distal to the dialysis access owing to diversion of blood
into the fistula.  The aetiology is iatrogenic and the fistula usually requires
banding to reduce flow or to be tied off completely in more severe cases.
Venous hypertension can occur with all types of AVF and grafts. The most
severe form occurs in combination with central vein stenosis secondary to
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previous central venous catheter insertion. This can usually be treated with
angioplasty and stenting.
High output cardiac failure has been associated with high AVF flow. It is
believed to be more common with high flow upper arm AVF and grafts. The
literature mostly describes improvement in cardiac failure symptoms after
AVF closure81-82 in those patients as having been selected with worsening
problems of congestive syndrome. In other case studies, it has been reported
that decrease in the cardiac output with the shunt closure that is less than the
blood flow in the unclamped fistula is an indication of high output cardiac
status83. However, this has not been validated.
Local effects of AVF formation
AVF formation has direct effects on multiple vessels, not only the artery and
the vein used to form the AVF. Blood flow rate of fistula is expected increase
gradually and can vary from 300 ml/min to even more than 2000 ml/min.
Chronic changes in large artery blood flow rates induce adjustments in arterial
diameter 84.  Blood flow regulates vessel diameter through changes in shear
wall stress 84.  Comparison of flow in the radial artery with AVF and flow in the
contralateral arm (as control) showed a six-fold increase in blood flow on the
fistula side compared to the control 84.  This was associated with a 1.4-fold
increase in the internal radial artery diameter. There was also evidence of
structural remodelling, (intima-media thickening) of the arterial wall. Kim et al
showed that increased radial artery intima-media thickness is closely
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associated with early failure of radiocephalic AVF in haemodialysis patients
85.
Endothelial dysfunction has been linked with the initiation and acceleration of
the atherosclerotic process 86.  Ene-Iordache et al suggested that the radial
artery dilates in such a way as to maintain the peak wall shear stress constant
and  that endothelial cells sense this maximum rather than time-averaged wall
shear stress, greatening the endothelial response 87.
AVF creation and effects on cardiac function
One of the first studies done on animals was by Guyton et al who
demonstrated up to 82% compensatory increase in cardiac output in
response to opening an artificial arterovenous fistula88.
The literature on the systemic effects of AVF formation in human being is
limited. All the studies done prospectively were limited by the number of the
patients studied, the frequency and duration of the follow up and the
techniques used to assess cardiovascular structure and function.
Nevertheless, they do provide some insight into the systemic changes
associated with AVF formation. It is now more evident that haemodialysis and
AVF formation affect cardiac function.  Six weeks after AVF formation Sandhu
et al demonstrated that cardiac index and stroke volume index had increased
and there was a significant effect on systolic and mean systemic arterial
pressure89.  .  A study by Savage et al confirmed the possibility that the
creation of an AVF in CRF patients may predispose to myocardial ischemia
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caused by an adverse imbalance between subendocardial oxygen supply and
increased oxygen demand 90.
Iwashima et al showed that creation of an AVF has significant effects on
cardiac systolic and diastolic performance and detected brain natriuretic
peptide (BNP) release stimulated by LV diastolic dysfunction 91.
1.5.3.2 Arteriovenous Grafts (AVG)
Grafts are used as an alternative when AVF formation is unfeasible (e.g.
vascular mapping reveals vessels not suitable for AVF). They allow selection
of arteries and veins to be joined together. They can be made of synthetic
material such as polytetrafluoroethylene (PTFE) or biological material
(biograft). Depending on the vessels selected, different anatomical variations
can be used to form a graft. For example, forearm loop graft is formed
between brachial artery and cephalic vein and straight forearm graft is formed
between radial artery and cephalic vein. Lower extremities can also be used
for placing straight or loop grafts. Other unusual and rarely practiced grafts
are necklace and grafts between lower and upper body blood vessels.
However, the risks associated with AVG formation, complications and failure
rates are much worse than for AVF. In a study it was shown that patients with
an AV fistula and who were older than 65 years had a risk of access failure
that was 24% lower than similar patients with an AVG92. The Canadian
haemodialysis morbidity study demonstrated a 71% lower failure rate of AVF
compared to AVG after adjustment for age, gender and comorbid
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conditions93. A recent series demonstrated that 77% of AVG required surgical
or radiological intervention to maintain patency at one year.  Additionally, 45%
of AVG permanently failed, requiring replacement during this interval 94.
1.5.3.3 Venous catheters
Cuffed venous catheters (CVC) are recommended to provide only temporary
vascular access, with the advantages of ease of insertion and immediate use.
Short term use only is advised because of the high rate of complications
associated with CVC use.
Infection is the most serious common complication associated with using
CVC. Using these catheters expose patients to enhanced risk of catheter
related sepsis including bacteraemia and metastatic infection. In the HEMO
study it was demonstrated that catheters were present in 32% of all study
patients admitted with access-related infection, even though catheters
represented only 7.6% of vascular accesses in the study95. The 11th annual
report from the UK renal registry highlights this fact even further. It reported
that 4.2% of MRSA bacteraemia in the UK happened in dialysis patients and
of those 70% were dialyzing through a central venous catheter, the majority of
which was a tunnelled line (59.8%). The relative risk of MRSA bacteraemia
was about 100 fold higher for a dialysis patient in comparison to the general
population and 8 fold higher for a patient using a catheter in comparison to a
fistula96. Actively avoiding infection in  dialysis patients is very important as
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mortality secondary to sepsis in this cohort  of patients is 100 to 300 fold
higher than in general population97.
Vascular catheter malfunction secondary to peri-catheter fibrin sheath and
thrombus formation is common and often limits duration of catheter utility 98.
They concluded that most infection-related hospitalizations were not
attributed to vascular access. However, the frequency of access-related,
infection-related hospitalizations was disproportionately higher among
patients with catheters compared with other forms of access.
Another serious and common complication associated with using central
venous catheters is subclavian vein stenosis. Almost 25% of dialysis patients
with dysfunctional fistulae were found to have subclavian stenosis in one
study, all with a history of previous subclavian vein catheterisation99. Another
study demonstrated that up to 42% of patients undergoing tunnelled catheter
insertion, had some degree of unexpected stenosis and/or angulation of the
central veins and it recommended using venography immediately prior to the
catheter insertion to detect unexpected and clinically significant anatomical
abnormalities particularly in those patients with a history of previous tunnelled
catheter insertion100. Overall, AVF is recommended over catheter use long
term for haemodialysis because of better dialysis outcomes and lower
associated complication rates.
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2 Thesis Aim
2.1 Hypothesis
This thesis has been planned to test the following hypothesis:
Formation of an AVF and the subsequent degree of flow through it
is capable of inducing significant microvascular, macrovascular
and myocardial, structural and functional changes.
2.2 Research questions
To test this hypothesis, the following interrelated research questions will be
addressed:
Primary End Point
? Is AVF formation associated with change in arterial stiffness? If so,
how?
Secondary End Points
? Are there any other changes in systemic haemodynamics that can be
attributed directly to AVF creation?
? What are the changes in flow of AVF and local circulation over time?
? Are there changes in cardiac function that can be associated with AVF
formation or fistula flow?
? Can we identify increased cardiovascular risk by assessing and
monitoring fistula flow or microcirculatory function?
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3 Methodology
All methods are dealt with in detail in this chapter and then referred back to
for reference in the relevant results sections. Certain methods and techniques
were used in more than one study outlined below.
3.1 Study design
A research protocol was created for a single centre, prospective,
observational study to take place over a 18 months period.  The described
study has been initiated and conducted in compliance with the written
protocol, the Research Governance Framework, the International Conference
of Harmonisation, Good Clinical Practice and all applicable Derby Hospitals
NHS Foundation Trust Research Office requirements.
Ethical approval was sought and granted for all aspects of the research
detailed in this thesis. Application was made to the Central Office of Research
Ethics Committees (COREC). Single centre research ethics committee
applications were made for the study. Site specific assessments were
undertaken and submitted. Approval from the Derby Hospitals NHS
Foundation Trust Research and Development Department was also sought
using the centralised research and development application form that was
integrated into the COREC application system. Joint sponsorship was granted
between the Hospital Trust and the University of Nottingham to allow for the
collection, analysis and storage of data and pathological samples (plasma
and serum) within both institutions.
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3.2 Subject selection
Approximately 100-130 fistula formation procedures are performed each year
in Derby hospitals.  We planned to study up to 50 patients over a period of 18
months. These included adults of any age, with CKD stage 4 and 5 disease
who require would haemodialysis.  Study subjects were identified from renal
outpatient clinics at Derby City General Hospital.  Patients required a fistula in
Derby were listed as part of routine work-up for renal replacement therapy
(RRT).  Thus identifying subjects for recruitment was fairly straightforward.
Subjects were provided with verbal and written information regarding the
research study.  A full week was given for patients to consider entry into the
study and review the consent form. After one week they were then invited to
attend for a recruitment visit.  At this visit patients ? informed consent was
taken.  There was no change or reduction to the standard care provided to
study patients as they progress to RRT.
Exclusion criteria were kept to a minimum in order to gain sufficient data and
reveal as fully as possible, the effects of AVF formation.
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Exclusion criteria
? Age <18
? Recent acute illness that required treatment, without full recovery.
? Medically unstable patient.
? Cardiac transplantation.
Inclusion criteria
? Male and female patients aged >18
? Any patient with CKD 4-5 who is clinically stable, including;
o AVF pending,
o any cause of renal failure,
o any co-morbid factors.
3.3 Subject withdrawal
Participants wishing to withdraw were free to do so at any time.  This caused
no detriment to their usual standard of care.
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3.4 Outline of research study
This study was powered to the measurement of arterial stiffness by means of
pulse wave velocity.  A minimum of 29 patients were required for statistical
validity (see statistical consideration - section 3.31).  Ethical approval was
given for recruitment of up to 50 patients into the study.  Renal patients at
CKD 4/5 (approaching end stage renal failure), prior to their fistula formation
procedures, were being approached.
Patients were to be assessed before and after fistula formation.  Assessment
included cardiac function, full vascular assessment, centrally and of the fistula
limb locally.  Distal systemic effects in the opposite limb were also evaluated.
Well-established techniques were used to assess these and relevant data are
collected. Comparison of the data pre and post fistula formation was made
and any changes that result was highlighted.  Repeated assessments took
place at stages as outlined in table 3.1 using the same techniques each time.
Baseline assessments could then be compared to the results at each stage.
3.4.1 Pre assessment
Assessment prior to fistula formation with echocardiography provides a
baseline for cardiovascular performance of our study patients.  Vascular
surgeons require thorough pre-fistula assessment and vascular mapping
before surgery to ensure feasibility for AVF. USS Doppler training undertaken
over several months has allowed me to perform the relevant vascular
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assessment on the study patients.  Inter-observer error is also reduced by
performing all vascular mapping for the study.
Data relating to macrovascular and microvascular function was gathered at
this stage using a range of non invasive, tried and tested techniques as
described.  They include laser Doppler imaging, pulse wave analysis with
augmentation index, pulse wave velocity and finometry.  Bioimpedance was
also used to measure total body water and body composition.
3.4.2 Newly formed AVF
Two weeks post AVF surgery was the first point of re-assessment (this is pre-
dialysis).  This includes flow and vascular analysis using same techniques;
pulse wave analysis and velocity, finometry, ultrasound Doppler and laser
Doppler imaging and echocardiography. Bioimpedance is re-measured.
3.4.3 Mature AVF
A third assessment took place when the fistulae had matured, this normally
occurs by 9 weeks post surgery.  Dialysis may have commenced at this time.
All analyses using the same techniques were repeated.  Cardiovascular
assessment with Echocardiography was repeated.
Any complications that occurred throughout the study with dialysis or fistulae
of patients (thrombotic occlusion, infection, failure to mature etc) were
recorded.  Those patients that suffered AVF failure, as a result, exit the main
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study but monitoring continued.  Re-entry to the study occurred if a new AVF
was to be created.
3.5 Data collection
1. Initial data collection, pre AVF:
? Demographic information.
? Cause of renal disease.
? Dates of planned fistula and start date for haemodialysis.
? Past medical history, including vascular disease and all relevant risk
factors.
? Full drug history, including any changes prior to and throughout study.
? Details of previous cardiac investigations (echocardiograms, LVEF,
stress tests, angiography)
? Baseline routine blood results (full blood count, electrolytes,
coagulation).
? Vascular mapping data.
? Arterial stiffness measuring pulse wave velocity and augmentation
index.
? Haemodynamic function and baroreflex sensitivity.
? Cardiac functional assessment with 2-dimensional echocardiography.
? Microcirculation and endothelial function using laser Doppler imaging
plus iontophoresis.
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2. Data collection 2/52, post AVF surgery:
? Dialysis details if initiated and QA calculation.
? Routine blood results (full blood count, electrolytes, coagulation).
? Pulse wave velocity and augmentation index.
? Haemodynamic function and baroreflex sensitivity.
? Vascular assessment with laser Doppler (LDI).
? USS Doppler with colour flow.
? Cardiac functional assessment with 2-dimensional echocardiography.
? Body composition using BIA.
3. Data collection, 9/52, mature AVF:
? Dialysis details if initiated- (time at ESRF, time at initiation RRT,
monthly kt/v, mode of access including changes, complications if any,
blood flow and QA, average interdialytic gain, use of anticoagulant).
? Routine blood results.
? Pulse wave velocity and augmentation index.
? Haemodynamic function and baroreflex sensitivity.
? Cardiac functional assessment with 2-dimensional echocardiography.
? Laser Doppler imaging.
? USS Doppler with colour flow.
? BIA.
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Additional measurements at each stage
? Regular review of drug history with documentation of any changes.
? Details of any vascular events, complications or access problems and
the treatment given.
? Any events or changes to regular dialysis program.
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from CKD
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AVF
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Table 3.1 Outline of the study
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3.6 Assessment of Cardiovascular Function
3.6.1 Echocardiography
2-dimensional echocardiography is used to assess cardiac function pre and
post fistula formation and results compared.  Commercially available
equipment, Vivid 3® ultrasound machine with a dedicated cardiac probe ((1.5-
3.6 MHz 3S probe, GE medical systems, Sonigen, Germany) is used.  Each
patient is to have three echocardiogram assessments over the study period.
Any prior echocardiograms of study patients provided additional information
only.  Measurement aims are simplified to provide only the data we require,
this includes:
1) Regional left ventricular function assessed by fractional shortening in
each LV region at rest.
2) Global LV ejection fraction.
Comment on global LV systolic function. Standard apical 2-chamber and 4-
chamber views (to visualise the LV endocardial border in 2 planes at 900 to
each other) are performed and recorded onto DVD for off-line analysis.
Ejection fraction (EF) is calculated using LV volumes at end systole and end
diastole from M-mode echocardiography images taken, according to the
recommendations of the American Society of Echocardiography101. All
measurements with the patients positioned in the left lateral position.
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3.7 Assessment of arterial stiffness
3.7.1 Pulse wave velocity
PWV is a well-recognised technique for obtaining a measure of arterial
stiffness between two locations in the arterial tree.  The velocity of the pulse
wave along an artery is dependent on the stiffness of that artery.  Arterial
stiffness, as mentioned before, is directly associated with increased risk of
cardiovascular disease.  Aortic pulse wave velocity measurement has been
shown to be a strong independent predictor of cardiovascular and all-cause
mortality in patients with end-stage renal disease on haemodialysis 102
The SphygmoCor® Pulse Wave Velocity System provides a comprehensive
assessment of arterial stiffness measured and useful assessment of the
critical cardiovascular variables.  It works by measuring the velocity of the
blood pressure waveform between any two superficial artery sites, using a
single-lead ECG and then tonometry to measure the pressure pulse
waveform sequentially in the two sites.  The tonometer is a delicate pressure
transducer which is sited in a pen shaped probe, allowing ease of
measurement when placed over the respective artery.
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Figure 3.1 Principle of applanation tonometry; the artery is partially compressed
against a hard structure.
Three blood pressure (BP) recordings are taken using an automated AND®
UA-767 oscillometric device.  A 3-Lead electrocardiograph (ECG) is attached
to the subject and the surface distance between pulse points is measured
using tape measure while the patient is supine.  Thus calculations of velocity
can be made (velocity= distance/ time).  A single operator performs all
haemodynamic measurements, reducing inter-observer error.
3.7.2 Aortic Augmentation Index
Peripheral wave reflection leads to augmentation of the aortic pressure wave.
Augmentation index is a measure of the sum of the incident wave and the
reflected wave, creating a systolic peak.  This peak is thought to be a
measure of the additional load to the left ventricle as a result of peripheral
wave reflection.  Augmentation index has been correlated with PWV as a
marker for arterial stiffness as it is the vessel stiffness that affects the speed
of the reflected wave.
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Figure 3.2 Standard arterial waveform for middle aged normotensive.
3.7.3 Reproducibility
In order to validate the results obtained using this technique, the inter-
observer error between an experienced operator and investigator was
assessed.  Each operator made two PWA measurements on 10 consented
subjects. Intraclass correlation coefficient analysis demonstrated a strong
correlation between the two operators (0.86).
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3.8 Local and distal microvascular assessment
3.8.1 Assessment of microcirculatory function
Microcirculatory function may be assessed indirectly (via surrogate humoral
markers including asymmetric dimethylarginine and endothelins) or directly by
assessing the vasodilator response to various stimuli, including ischaemia
(typically post-occlusive), hyperthermia or drugs. Iontophoretic drug
provocation with acetylcholine (ACh) and sodium nitroprusside (SNP) allows
separation of the endothelial-dependent (ACh) and endothelial-independent
(SNP) pathways. Both Laser Doppler flowmetery (LDF) and Laser Doppler
imaging (LDI) utilize a low-power laser to detect blood flow in dermal
capillaries, either at a fixed point (LDF) or scanning over a limited area (LDI).
Their use has been demonstrated in CKD103. There are however, significant
methodological constraints with both techniques, and thus specific care must
be taken with many factors including the environment, site of assessment and
drug delivery104.
Cutaneous microcirculatory changes may have a direct bearing on the
development and clinical course of  vascular calcification (VC). The
maintenance of flow to vulnerable critical visceral circulations is essential to
maintain health, and abnormalities of microcirculatory function may be
important in the overall pathophysiology of this process and the development
of calcific uraemic arteriopathy. There are currently no data available on the
distribution of directly calcified microvessels in patients with CKD.
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Abnormal cutaneous microcirculation has been identified in patients receiving
HD105-106 and further reductions in microcirculatory function have been shown
to be present in HD patients with large-vessel VC107.
The cardiac microcirculation is becoming increasingly recognized as being
important in the development of demand-induced myocardial ischaemia108.
Impaired coronary flow reserve is determined by the maximum flow resulting
from stress vasodilatation of both epicardial coronary arteries and the
microcirculation. In health, 90% of MBF takes place through vessels <150
μm109-110. Myocardial ischaemia is well recognized as occurring in HD patients
in the absence of large-vessel coronary disease111.
There are no data currently available on the presence of significant
calcification within the coronary microcirculation itself. Impaired
microcirculatory function in ESRD patients is associated with increased LVM
and arterial remodelling112.
The assessment of subcutaneous dermal capillaries is a primary method for
the assessment of the microcirculation. These vessels are representative of
the microvascular supply to the heart113 and kidneys114. This might allow
study of the relatively accessible microcirculation to provide a window to
critical central vascular beds. Abnormalities of endothelial function
demonstrated using LDF can provide additional quantification of CV risk when
used in conjunction with conventional risk scores115. LDF also appears to be
able to document endothelial cell dysfunction in ESRF patients prior to clinical
evidence of CV disease or diabetes mellitus116.
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3.8.2 Laser Doppler imaging (LDI)
Microcirculation is a collective term used to describe the smallest components
of the cardiovascular system, namely arterioles, capillaries and venules.  In
order to identify the vascular changes related to microcirculatory flow and
endothelial function we are using Laser Doppler Imaging (LDI) technique with
iontophoresis of vasoactive drugs namely acetylcholine (Ach) and sodium
nitroprusside (SNP).  LDI is a fairly recent development 117 but results have
been found to be closely correlated to capillary microscopy measurements of
blood flow 118.
This technique will not only provide data regarding the local effects of the new
fistula but comparison with data from the non fistula arm will also provide
information on systemic and distal effects. Combining Iontophoresis of both
Ach and SNP with this technique allows both endothelial dependant and non
endothelial dependent vasodilatation responses to be measured.
Prior to starting the study, appropriate training was taken through a teaching
course organised by the manufacturer in Stockholm  ? Sweden.
Studies are undertaken in a temperature controlled room following 10 minutes
of rest.  A laser beam scans over a designated area generating multiple
measurement sites.  By means of mirrors connected with stepper motors, the
laser beam moves sequentially over the tissue over a measured site, over a
set time 119.  Consecutive scans are then acquired.  Dose-response
information for vasodilator reactivity is obtained using transcutaneous
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iontophoretic administration of the Ach and SNP.  Two electrodes are applied
to the surface of the forearm, filled with either 1% Ach or SNP and they are
connected to a DC electric source for iontophoresis. A fixed current of 0.02
mA is used for 8 minutes for iontophoresing each drug.  Cumulative dose-
response curves are analysed automatically by the built-in software and data
comparison can then be made between study days for individual subjects.
3.9 Haemodynamic assessment
3.9.1 Finometry
Systemic haemodynamic function is assessed non-invasively using a
Finometer® (TNO Instruments Amsterdam, Netherlands).  This technology
utilises a finger-clamp method and allows detection in changes to digital
arterial diameter by means of an infrared photoplethysmograph.  This is
opposed by an ultra-fast pressure servo controller that changes the pressure
of an inflatable air bladder (also mounted in a finger cuff).  Pulse wave
analysis of the resultant arterial waveform and reconstruction of a central
aortic waveform allows calculation a full range of haemodynamic variables on
a continuous basis, for each heart beat 120.  These include pulse rate (HR),
blood pressure (BP), stroke volume (SV), cardiac output (CO) and total
peripheral resistance (TPR).  All the data is subsequently downloaded to the
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PC based analysis program Beatscope™ and results are averaged over a
defined time period.
This process is conducted in a controlled environment after the participant
has not eaten or consumed alcohol or coffee for at least 12 hours. Cuffs
attached to the Finometer? are placed on an appropriate finger (ie middle
finger, non-AVF side) and on the upper arm of the patient (non AVF).
3.9.2 Baroreflex Sensitivity (BRS) calculation
Autonomic dysfunction is common in patients receiving dialysis, and those
with significant CKD. Short-term regulation of BP is largely controlled by
appropriate autonomic nervous activity through the baroreflex arc121.
Baroreflex sensitivity (BRS) is therefore well recognized as an integrated
assessment of the autonomic nervous system122. BRS is not constant, and is
affected by multiple factors. The involvement of drug treatment123, endothelial
dysfunction/paracrine factors124, posture125 and age126 have all been
demonstrated. Such dysfunction is associated with an increased incidence of
cardiac arrhythmias127, falls propensity, intradialytic haemodynamic
instability128, cardiac damage, metabolic syndrome129, CV events and all-
cause mortality after myocardial infarction130 and in heart failure.
BRS as a marker of the fundamental control of BP is of great physiological
significance in the study of HD. Impaired BRS has been demonstrated in
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patients who are unstable on HD131.  Furthermore, transfer from conventional
haemodialysis three times weekly to nocturnal haemodialysis increases
BRS131, although further work is required to evaluate outcomes associated
with what are at least theoretical benefits in terms of CV outcomes.
The finometer measures continuous interbeat interval (IBI) and beat-to-beat
blood pressure changes.  Baroreflex sensitivity (BRS) is a calculation of the
regression slope between these two differentials.  BRS software is integrated
into the device and has been made available to use as a stand-alone DOS
based offline analysis tool by Karl Wesseling (TNO instruments, Amsterdam).
Three consecutive changes in the R-R interval in the same direction are
required before a phase shift calculation (incorporated into the software) is
performed and thus BRS is non-invasively measured with accuracy and
precision.  These variables vary with time so a recording of at least 10
minutes taken at rest is performed.  BRS measured in this way is a composite
marker of the overall activity of the autonomic nervous system 132.
3.10 Body composition and hydration status assessment
3.10.1 Bioimpedance
Measurements are made using the InBody S20 mutlichannel multisegmental
analyser.  This provides data on intracellular/extracellular fluid ratios, total
body water (TBW), skeletal muscle and fat mass for the whole body, and
segmentally for trunk and each limb. This technique is fully automatic
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therefore interobserver variability is likely to be low.  The manufacturers claim
a measurement error of 1% with reproducibility of 99%.
It has been successfully validated against the  ?gold-standard ? of deuterium
dilution for TBW assessment 133. It has also been validated against DEXA for
total and regional body composition in healthy subjects 134 and peritoneal
dialysis patients 135.
3.11 Fistula flow assessment
3.11.1 Doppler ultrasound
Blood flowing through the fistula is determined by the sum of the flow
resistance of the arterial system between the left ventricle and the
anastamosis, the flow resistance of the anastamosis itself and the flow
resistance of the venous system between the anastamosis and the right
atrium 64.  Colour flow Doppler provides accurate imaging and flow volume
measurement of vascular access in haemodialysis.  Doppler ultrasound has
become the standard of care for evaluation of AVF dysfunction and is
essential in the preoperative evaluation for access placement 136.
As well as pre-operative vascular mapping, post operative evaluation of the
fistula flow is carried out using an ultrasound colour-flow scanner.  Fistulae
are scanned with a linear array transducer, longitudinally and transversely All
vascular flow measurements were done by a single experienced user using a
dedicated vascular probe (4-10 MHz 10L-Linear Probe, GE medical systems).
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Vascular ultrasound/Doppler training was by delivered by highly experienced
senior sonographers for the period of 6 months. Training has been
undertaken with regards to vascular mapping prior to AVF creation,
measuring blood vessel diameter and timed average velocity of blood flow
and calculating flow rate. Cross sectional area measurements are made by
tracing the vessel outline under maximum resolution and the accuracy and
quality of the images taken were assessed. Changes in velocity, volume,
fistula size and are recorded at each assessment stage and results
compared.
3.12 Laboratory Tests
Routine blood tests performed as part of standard patient care will be
recorded.  No additional blood tests will be requested as part of the study at
this time.  However, it is possible that testing for BNP, CRP or other
biochemistry may become relevant as this study progresses.  Thus, we are
saving serum from participants during the study to allow analysis later, if
required.  We will not use these samples for any genetic testing or to produce
results that would have a direct prognostic effect on a particular patient.  If
these samples are not used they will be discarded at the end of the study.
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3.13 Statistical considerations
Continuous consultation with the University of Nottingham research
statistician occurs in relation to this study.  Assistance was initially required in
regards to power calculations and analysis planning.
3.13.1 Primary outcome measure
 ?To detect a significant difference in arterial stiffness, as measured by pulse
wave velocity. ?
A change of one metre per second was to be identified, comparing patients
pre AVF to the repeat assessments performed at two weeks and nine months
post AVF surgery. Using data generated by previous published research
from Derby we are able to perform the following power calculations for this
study. Using work by Sigrist et al 137 we can use the mean value and standard
deviation obtained for carotid-radial PWV of patients with pre-dialysis CKD.
Mean PWV = 9m/s
Standard deviation = 1.6 m/s
Observing a significant difference of 1m/s, at 6/52 and 6/12.
Power = 90%
Significance level of = 5%
The required sample size was 29 patients. Adjusting for a failure rate of 30%
for primary AVF (local rates) and 15% annual mortality the final sample size
needed for this study was 50 patients.
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3.13.2 Secondary outcomes measures
1. Cardiovascular function
Changes in LV systolic function (global ejection fraction). Pre and post AVF
formation echo data was compared.
2. Microvascular function
Dose response curves generated by laser Doppler allowed comparison of
microcirculatory flow, comparing results pre and post AVF as well as
comparison of the AVF arm to the non AVF arm.
3. Fistula flow
Vessel diameter, cross sectional area, timed average velocity and volume are
measured by  the Doppler ultrasound.  Changes over time were analysed.
4. Haemodynamic function
Average recording over 10 minutes provided data on heart rate (HR), blood
pressure (BP), stroke volume (SV), cardiac output (CO) and total peripheral
resistance, allowing data analysis.
5. Autonomic function (BRS)
Calculation of average change in interbeat interval for a change in blood
pressure of 1mmHg compared to ms/mmHg.  Changes in BRS associated
with AVF formation and maturation will be assessed.
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Chapter 4
Effects of AVF creation on systemic haemodynamics
and left ventricular systolic function
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4 Results: Effects of AVF creation on systemic haemodynamics and left
ventricular systolic function
4.1 Introduction
Upper extremity native arteriovenous fistula (AVF) is the vascular access of
choice, supported by the KDOQI of the National Kidney Foundation138. The
use of definitive vascular access in HD patients, rather than tunnelled central
venous catheters, is associated with sustained reduction in mortality over at
least three years75. This difference in survival has previously been entirely
attributed to differences in access related sepsis.  Little is currently known
concerning the systemic structural and functional cardiovascular changes that
occur as a consequence of AVF formation. Several case reports indicate that
very high fistula flows (Qa) can be associated with inducing a high cardiac
output status and subsequent precipitation of cardiac failure88-89 139, and the
presence of an AVF may modulate sympathetic outflow88 and markers of
volume status such as BNP140.
However, there have been no prospective studies of the totality of effect of de
novo AVF formation on cardiovascular system structure and function.
It is well recognised that dialysis patients display hugely elevated rates of
cardiovascular mortality141. It is also becoming appreciated that this rate of
cardiovascular attrition is not driven by the same variety of risk factors, or
pathophysiological processes that are important in the general population142.
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Cardiac failure develops in as many as 25-50% of HD patients and confers a
dramatic reduction in probability of survival143. HD patients are particularly
susceptible to demand myocardial ischaemia. In addition to the high
prevalence of coronary atheroma144 , diabetic dialysis patients have been
shown to have a reduced coronary flow reserve, even in the absence of
coronary vessel stenoses145.
The aim of this study is to prospectively investigate the acute effects of AVF
formation on systemic haemodynamics and left ventricular function as these
factors are crucial in the pathophysiology of CV diseases in this group of
patients.
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4.2 Methods
4.2.1 Subjects
Recruitment of the initial 43 patients is covered in chapter 3, section 3.2 and it
is not repeated here.
Successful AVF formation was defined as an arteriovenous anastomosis with
clinical (palpation and auscultation) and Doppler ultrasound confirmed blood
flow two weeks postoperatively.
All the subjects were studied two weeks prior to their planned operation date
and restudied 2 weeks postoperatively. No acute illness or major post
operative complication was recorded during the follow up period. In addition,
all the vasoactive medications (B-blockers, calcium channel blockers,
angiotensine converting enzyme inhibitors, aldosterone receptor blockers,
diuretics and alpha blockers) remained unchanged during the study period.
4.2.2 Haemodynamic studies
On the study days, patients were allowed to rest in bed for 15 minutes before
data collection. Three blood pressure recordings were taken using an
automated AND® UA-767 oscillometric device on the non-fistula arm.
Haemodynamic measurements were taken non-invasively using Finometer®
(Finapres Medical Systems, Arnhem, the Netherlands). This technology uses
pulse-wave analysis obtained at the digital artery to measure beat to beat
blood pressure and heart rate. Modelflow™ derived changes in cardiac output
62
(CO), stroke volume (SV) and total peripheral resistance (TPR) were
calculated using a reconstructed aortic pulse wave. BRS values were
recorded using software analysing the relationship between inter-beat interval
variability and beat to beat changes in systolic BP146.
4.2.3 Echocardiographic and Doppler ultrasound studies
All studies were conducted during first and second visits using Vivid 3®
ultrasound machine with a dedicated cardiac probe ((1.5-3.6 MHz 3S probe,
GE medical systems, Sonigen, Germany). M-mode ventricular parameters
were measured according to the recommendations of the American Society of
Echocardiography101. A single experienced operator carried out all
measurements with the patients in the left lateral position. Echocardiographic
evaluations were performed by another experienced observer (TE) who was
completely blinded to operation outcome, examining the digitized images
obtained for off line analysis. Ejection fraction (EF) was calculated using LV
volume at end systole and end diastole obtained from M-Mode
echocardiography images.
All vascular flow measurements were done by a single experienced user
using a dedicated vascular probe (4-10 MHz 10L-Linear Probe, GE medical
systems). All patients were studied in sitting position. Examination followed
the blood flow from the afferent artery into the anastomosis, the access vein
and the draining veins. All the flow rate measurements were done in a straight
access segment free of turbulent flow. The transverse diameter of the vessel
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was multiplied by the average flow velocity to obtain the volume flow rate in
ml/min.
4.2.4 Body Composition and blood tests
Bioelectrical impedance was measured using InBody S20® body composition
analyser (Biospace, Korea) to detect changes in total body water and soft
tissue composition. Blood samples were collected during each study session
and biochemical analysis including full blood count, electrolytes, urea,
creatinine, bone profile, albumin, C-reactive protein and Troponin T serum
levels were measured.
4.3 Statistical analysis
Normality of distribution of the data was tested using Shapiro-Wilk tests test.
Results are expressed as mean ± SD. For comparing pre- and post operative
data, paired t-test was used. An alpha error at P<0.05 was judged to be
significant.
Simple linear relationship between different variables was measured using
Pearson ?s coefficient of correlation.
Stepwise multivariate regression analysis was performed to determine
independent predictors of fistula blood flow (Qa). Factors for the models were
considered either because they were established determinants of the
dependant variable (Qa) or they achieved significant value in the initial
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regression analysis using  ?enter ? method. All statistical anlysis was
performed using the SPSS software package, version 12 (SPSS Inc., USA).
4.4 Results
4.4.1 Baseline characteristics
All patients had an end-to-side anastomosis and the operations were done as
a day case procedures under local anaesthetic. One patient died before
attending the second study session, from unrelated causes. Two patients who
had an unsuccessful AVF operation initially, were re-recruited and
consequently had a successful AVF formed.
30/43 patients had successful AVF operation performed (22/29
brachiocephalic, 3/3 brachiobasilic and 5/11 radiocephalic). Patients with
failed AVF (13/43) procedures were utilised as sham operated controls.
Demographic, biochemical, and CV risk factors characteristics of the study
participants according to their operation outcome are listed in table 4.1.
Mean age was 68±13 years. Of those studied, 40% were female and 60%
male.  The causes for chronic renal failure amongst the cohort were diabetic
nephropathy 37%, primary glomerulonephritis 14%, unknown 21% and other
causes (polycystic disease, vasculitis, renovascular diseases and obstructive
uropathy) 28%. None of the patients in the cohort had a documented clinical
diagnosis of cardiac failure. However, our analysis of the echocardiographic
images obtained during baseline sessions showed that EF was less than 50%
in 15/30 patients with successful AVF.
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Unsuccessful
AVF (n=13)
Successful
AVF (n=30)
P
Age 66.7±15 68.7±12 0.7
Gender(male:female) 6:7 20:10 0.2
BMI 30.5±5.2 28.6±6.3 0.3
Ischemic heart disease 39% 37% 0.9
Diabetes 46% 37% 0.5
Hypertension 92% 77% 0.1
Dyslipidaemia 69% 70% 0.9
Smoking 69% 60% 0.6
ACE inhibitors/ARB 62% 73% 0.4
Pre eGFR (ml/min) 17±4 17±4 0.2
Albumin (g/l) 37±3 36±4 0.7
Hb (g/dl) 11.8±1.3 11.4±1.4 0.3
Table 4.1 Demographic, biochemical and cardiovascular risk factors in both groups
BMI=Body Mass Index, ACE inhibitors=Angiotesin-Converting Enzyme inhibitors
ARB=Angiotensin Receptor Blockers, eGFR= estimated Glomerular Filtration Rate
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4.4.2 Haemodynamic data
The baseline and postoperative haemodynamic data in both patient groups
are summarized in table 4.2. These significant haemodynamic changes only
occurred in patients who had a successful AVF formation. Two weeks
postoperatively, peripheral systolic and diastolic BPs were both decreased (-
9.7±18 and -9.5±10.3 mmHg respectively). This was accompanied by a
similar reduction in central systolic BP -12.4±16.2 mmHg and central diastolic
BP -7.8±7.9 mmHg. Total peripheral resistance decreased (-0.2±0.021
mmHg.sec/ml, p=0.001) stroke volume tended to increase (12±30 ml,
p=0.053) and heart rate increased (4±8.0 bpm, p=0.01). This was associated
with an increase in cardiac output (1.1±1.5 L/min, p=0.001).
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Figure 4.1 Mean cardiac output (CO) in both groups pre and 2 weeks postoperatively
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Parameter Successful AVF Unsuccessful AVF
Pre Post % p Pre Post % p
Peripheral SBP 144±28 134±21 -5±13 0.006 137±19 138±20 1 0.6
Peripheral DBP 75±12 66±11 -12±13 0.001 74±12 75±13 -1 0.7
SV(ml) 113±33 124±41 11±22 0.053 116±41 116±41 1 0.9
HR(bpm) 60±11 64±10 8±14 0.01 61±11 59±7 -3 0.3
CO(l) 6.5±1.5 7.6±2 19±25 0.001 7±3 6.8±2.5 -3 0.7
CI(l/min/m2) 3.45±0.7 4.1±1.0 19±25 0.001 3.7±1.6 3.5±1.2 -3 0.7
TPR(mmHg.sce/ml) 1.0±0.2 0.8± 0.2 -17±18 0.001 1.0±0.4 1.1±0.7 15 0.4
BRS 5.6±3 5.8±2.5 10±38 0.4 5.8±3.4 6±3.1 25 0.2
EF(%) 45±13 52±12 6±8 0.001 45±13 45±14 -1 0.8
Table 4.2 Baseline and postoperative haemodynamic data in both groups
4.4.3 Body composition and laboratory data
There were no significant changes in total body water (intra and extra cellular
water) and soft tissue composition in either group postoperatively.
Furthermore, no significant differences in any of the biochemical and
haematological parameters were observed in either group postoperatively.
There was no change in renal function as measured by estimated GFR.
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4.4.4 Echocardiographic and Doppler ultrasound
Two weeks postoperatively, patients who had a successful AVF formation
demonstrated an increase in their ejection fraction (6.5±8.5%, p=0.001). This
was in contrast to those patients with unsuccessful AVF who showed no
change (figure 4.2). Not all patients exhibited an increase in EF, 5/30 had a
small mean reduction (-2.6±1.1%). These patients were older (75±9) with
higher baseline systolic BP and had stiffer arteries (see table 4.3). However,
their arterial stiffness indices, BPs and TPR were reduced after AVF
formation in similar way to the others.
Clinically, no case of cardiac decompensation was recorded following AVF
creation.
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Figure 4.2 Left ventricular ejection fraction (EF) in both groups
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pre and postoperatively
Parameter Increased EF Reduced EF
Pre Post Pre Post
Peripheral SBP 142±28 132±20 155±25 138±20
Peripheral DBP 76±13 64±12 74±3 69±6
Central SBP 132±27 118±19 143±23 134±19
Central DBP 73±14 65±12 75±3 70±6
CF-PWV(m/s) 12.2±3 10.9±3 13.4±2 12.1±2.4
AIx% 22±10 18±10 25±8 22±8
SV(ml) 117±27 127±23 84±27 86±12
HR(bpm) 60±13 64±10 60±10 62±10
CO(l/min) 6.6±1.5 7.2±1.4 5.2±1 6.2±0.5
CI(l/min/m2) 3.5±0.7 3.8 ±0.66 3.25±0.83 4.2±1.58
TPR(mmHg.sec/ml) 0.97±0.17 0.83± 0.17 1.18±0.4 0.93±0.3
Table 4.3. haemodynamic and arterial stiffness parameters pre and postoperatively
in the patients with increased EF compared to patients with reduced EF (n=5) two
weeks postoperatively.
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Mean AVF flow (Qa) varied according to the type of the fistula constructed;
with brachiobasilic fistulas exhibiting mean Qa of 1500±1100 ml/min,
brachiocephalic fistulas 1300±600 ml/min and radiocephalic fistulas 600±170
ml/min. Diameter of the artery and vein designated for the AVF formation and
blood flow through the artery preoperatively were statistically different
between both groups. These data are summarised in Table 4.3.
Unsuccessful
AVF (n=13)
Successful
AVF (n=30)
P
Artery diameter (mm) 33±10 45±12 0.007
Artery blood flow (ml/min) 43±22 77±44 0.01
Vein diameter (mm) 32±10 40±11 0.07
Table 4.4 Preoperative blood vessels diameter and arterial blood flow in both groups
On a multivariate regression analysis, the major determinant of the Qa flow
were diameter of the AVF itself and the blood flow in the supplying artery
(R2=0.63, p=0.001 and 0.02 respectively, (see table 4.4).  There was no effect
of cardiac performance on AVF blood flow.
Variables
Unstandardized
Coefficients
Standardized
Coefficients
P
B Std. Error Beta
AVF diameter 212.8 55.526 0.548 0.001
Post operative
arterial flow
0.351 0.145 0.347 0.022
Table 4.5 Multivariate analysis of factors affecting Qa
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4.5 Discussion
Although there has been some study of the effect of AVF formation on
isolated aspects of the CVS, this is the first study to prospectively investigate
the observed effects in detail on cardiovascular structure and function (both
peripheral and cardiac). Furthermore, it is the first study to exclusively
investigate the effects in patients without previous vascular access or
exposure to dialysis.  The utilisation of patients with primary technical failure
provides the opportunity to study those effects controlled against a group of
patients undergoing the same progression of uraemic factors, but without a
formed shunt.
From the physiological studies looking into compensation of CO and other
haemodynamic variables in animal models post AVF formation, it is believed
that increase in CO is mediated by two mechanisms88. The acute response
which happens within seconds of AVF formation is caused by increased in
venous return secondary to reduction in TPR and cardiac adaptation, in
accordance with Starling's principle. Subsequent responses appear to occur
secondary to neurohormonal and autonomic nervous system modifications.
The significant increase in the CO demonstrated in our study, is similar to the
observation made by the few other clinical studies which have looked into the
effect of AVF formation on cardiac output89 140 147 (utilising different techniques
to measure central haemodynamics).
The prevailing view that higher flow within the AVF is associated with high
output cardiac failure is widely held. However this assertion has not been
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previously tested in prospective rigorous study. Uniquely, we have
investigated the changes in systemic haemodynamics including CO
specifically in pre-dialysis population, without many of the confounders that
would be involved in using a dialysis based population (changing volume
status, resolution of uraemia, medication changes etc.). All patients who had
a successful AVF formed showed an increase in their CO, however there did
not appear to be any relationship between higher Qa values and CO. There
was no clinical evidence of cardiac decompensation, with no change in body
water. Echocardiography data demonstrated that even two weeks
postoperatively, there was a significant increase in EF.  This is similar to
changes noted in previous studies140 147.  The observed change in EF
continued to be persistent up to three months postoperatively when the
vascular access had matured (see chapter 6).
Preoperatively, 50% of the patients who had successful AVF formed had EF
values of less than 50%. In contrast to the common belief of avoiding AVF
placement in patients with impaired ventricular function, these patients
underwent proper assessment and had their AVF created. Echocardiography
data demonstrated that even two weeks postoperatively, there was a
significant increase in EF.  This is similar to changes noted in previous
studies140 147.  Interestingly, there was no clinical evidence of cardiac
decompensation, with no change in total or ECW water in any of the patients
studied.  The above finding suggests that the practice of withholding AVF
placement in older patients or those who have CV compromises may well
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need to be revised.  This point is more comprehensively discussed in the
following chapters of this thesis.
4.5.2 Conclusion
Formation of an AVF resulted in significant changes in systemic
haemodynamics. Overall the post AVF adaptations might be characterised as
potentially cardioprotective.
Left ventricular ejection fraction increased and there was no evidence of
acute cardiac decompensation in this acute setting, and further study of the
longer term CV responses to AVF formation are essential to improve our
understanding of the complex role that vascular access choices might make
on patient outcomes.
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Chapter 5
Effects of AVF creation on arterial stiffness, central and
peripheral blood pressures
75
5 Results: Effects of AVF creation on arterial stiffness, central and
peripheral blood pressures
5.1 Introduction
CKD patients are known to have a blood pressure values characterised by
elevation of systolic blood pressure and normal or even reduction in their
diastolic blood pressure148. These readings are associated with increased
stiffness of the large conduit arteries. The exact cause behind increase in
arterial stiffness in CKD patients is not completely understood but it is not
exclusively related to increase in blood pressure, increased wall stress or
other conventional CV risk factors such as blood glucose, body weight,
cholesterol or smoking149-150. Increased arterial stiffness leads to alteration of
central blood pressures, increasing myocardial oxygen demand whilst
reducing supply due to the reduction in diastolic blood pressure reinforcement
from the returning pressure wave. These factors increase the risk of
myocardial hypoperfusion151.
Studies of myocardial blood flow during HD in adult patients with normal
coronary angiograms152 and dialysis induced cardiac segmental ischaemia in
children on haemodialysis153, have highlighted the existence of demand
myocardial ischaemia during HD in the absence of atheromatous large vessel
coronary artery disease. Such repeated injury results in systolic dysfunction,
increased cardiac arrhythmias and markedly reduced survival154-155 .
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It is already been shown that increased arterial stiffness is associated with
impairment in creatinine clearance in patients with mild to moderate CKD
independent of age, blood pressure and other risk factors156.  It has also been
demonstrated that arterial stiffness increases across a range of patients with
different stages of CKD as eGFR increases58.
Furthermore, in patients with ESRD, for 1m/s increased arterial stiffness, all-
cause mortality-adjusted OR was 1.39 (95% CI, 1.19 to 1.62)60. When
hypertensive, ESRD patients treated with antihypertensives, it was the ∆PWV
which was a direct predictor of all cause mortality independent of reduction in
blood pressure157.
The impact of AVF creation on arterial stiffness (as a critical determinant of
potential demand ischaemia and increased mortality) has not been studied
before. The few studies that have been performed have tended to be small,
focus on only limited elements of the cardiovascular system and/or rely on
extrapolation of data derived from closure of troublesome AVFs in established
HD patients.
We already know that fistula creation is associated with significant
haemodynamic changes including reduction in BP and TPR and increase in
SV, HR and CO.  The aim of this study is to (1) detect any significant changes
in arterial stiffness in response to AVF creation and (2) look into the
association between change in arterial stiffness and other haemodynamic
variables.
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5.2 Methods
5.2.1 Patients
Recruitment of the initial 43 patients is covered in chapter 3, section 3.2 and it
is not repeated here.
Successful AVF formation was defined as an arteriovenous anastomosis with
clinical (palpation and auscultation) and Doppler ultrasound confirmed blood
flow two weeks postoperatively.
All the subjects were studied two weeks prior to their planned operation date
and restudied 2 weeks postoperatively. No acute illness or major post
operative complication was recorded during the follow up period. In addition,
all medications remained unchanged during the study period.
5.2.2 Study protocol
All patients gave consent prior to commencement. Patients were studies at
the same time of the day after abstaining from smoking, caffeine and smoking
for at least 12 hours. On the study days, patients were allowed to rest in bed
for 15 minutes before data collection. Three blood pressure recordings were
taken using an automated AND® UA-767 oscillometric device on the non-
fistula arm.
As a measure of arterial stiffness, the gold standard carotid-femoral pulse
wave velocity (CF-PWV) was taken using Sphygmacor® (AtCorTM, PWV
Inc., Westmead, Sydney, Australia) pulse wave velocity system.
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In addition, Aortic Augmentation Index (AIx) and central blood pressure were
measured from radial artery tonometry. All CF-PWV and AIx measurement
were repeated three times and the average calculated for subsequent
analysis.
This protocol was repeated for the subsequent study sessions.
5.3 Statistical analysis
Sample size was calculated with reference to the primary outcome of change
in PWV with formation of an AVF.  Details about the study power and the
statistical tests used in the analysis are discussed in chapter 3, section 3.13.
Stepwise multivariate regression analysis was performed to determine
independent predictors of change in CF-PWV (∆ PWV). Factors for the
models were considered either because they were established determinants
of the dependant variable (∆PWV) or they achieved significant value in the
initial regression analysis using  ?enter ? method. All statistical analysis was
performed using the SPSS software package, version 12 (SPSS Inc., USA).
5.4 Results
 5.4.1 Baseline characteristics
All patients had an end-to-side anastomosis and the operations were done as
a day case procedures under local anaesthetic. One patient died before
attending the second study session, from unrelated causes. Two patients who
79
had an unsuccessful AVF operation initially, were re-recruited and
consequently had a successful AVF formed.
30/43 patients had successful AVF operation performed (22/29
brachiocephalic, 3/3 brachiobasilic and 5/11 radiocephalic). Patients with
failed AVF (13/43) procedures were utilised as sham operated controls. For
demographics, biochemical and cardiovascular risk factors of the study
participants according to their operation outcome please see chapter 4,
section 4.4.1 and table 4.1.
5.4.2 Blood pressure
Table 5.1 shows the effect of AVF creation on central and peripheral BPs,
CF-PWV and AIx in both patients group pre and postoperatively. Significant
changes only occurred in patients who had a successful AVF formation.
Two weeks postoperatively, peripheral systolic BP was significantly reduced
(-9.7±18 mmHg) as was diastolic BP (-9.5±10.3 mmHg), see figure 5.1 and
5.2.
80
Parameter Successful AVF Unsuccessful AVF
Pre Post % P Pre Post % p
Peripheral SBP 144±28 134±21 -5±13 0.006 137±19 138±20 1 0.6
Peripheral DBP 75±12 66±11 -12±13 0.001 74±12 75±13 -1 0.7
Central SBP 133±26 121±19 -8±12 0.001 127±17 129±19 1 0.6
Central DBP 73±13 67±11 -9±11 0.001 76±12 75±13 -2 0.8
Table 5.1 Baseline and postoperative blood pressure data in both groups
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Figure 5.1 Peripheral systolic blood pressure (SBP) pre and postoperatively in both
groups
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Figure 5.2 Peripheral diastolic blood pressure (DBP) pre and postoperatively in both
groups
This was accompanied by a similar reduction in central systolic BP (-
12.4±16.2 mmHg) and central diastolic BP (-7.8±7.9 mmHg), see figure 5.3
and 5.4.
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Figure 5.3 Central systolic blood pressure (SBP) pre and postoperatively in both
groups
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Figure 5.4 Central diastolic blood pressure (DBP) pre and postoperatively in both
groups
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5.4.3 Arterial stiffness
Arterial stiffness markedly decreased following successful AVF formation. CF-
PWV was reduced by a mean of (-1.1±1.5 m/sec, p=0.004, figures 5.5). AIx
was also reduced (-3.7±5.4%, p=0.002) significantly in patients who had a
successful AVF formed (see table 5.2 and figure 5.6).
In a stepwise multivariate analysis, change in peripheral diastolic BP (∆D-BP)
and the presence of diabetes mellitus were independently associated with
observed ∆PWV (R2=0.393, p=0.001), with ∆D-BP independently contributing
by 25% to the model (R2=0.25, p=0.004).
.Parameter Successful AVF Unsuccessful AVF
Pre Post % P Pre Post % p
CF-PWV(m/s) 12.6±3.5 11.0±3 -8±13 0.004 10.8±2 10.9±2.4 1 0.7
AIx% 22±9 19±9 -15±30 0.002 25±9 23±9 -2 0.4
Table 5.2 Baseline and postoperative measurements of arterial stiffness indices in
both groups
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Figure 5.5 Carotid Femoral Pulse Wave Velocity (CF-PWV) pre and postoperatively
in both groups
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Figure 5.6 Aortic Augmentation Index (AIx) pre and postoperatively in both groups
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5.5 Discussion
This study prospectively investigates the effects of AVF formation on
peripheral and central haemodynamics and cardiovascular structure and
function. It exclusively investigates the effects in patients without previous
vascular access or exposure to dialysis.
We have demonstrated that both central and peripheral blood pressure fell
significantly after AVF formation. This can be attributed to the described fall in
TPR (see chapter 4). Interestingly even this fairly simple consequence of
AVF formation has been subjected to very little formal study. Ori et al also
showed reduction in systolic and diastolic blood pressure, but to a lesser
extent, possibly due to a smaller sample size (n=10)147.
We also looked into the association between AVF formation and CF-PWV
allowing correlation with changes in other haemodynamic variables. Savage
et al measured AIx in nine patients, reporting this composite marker of arterial
compliance and cardiac performance did not change significantly after AVF
formation158. More recently, Utescu et al demonstrated that successful AVF
formation was associated with reduction in CF-PWV and mean BP and a non
significant increase in AIx159. Interestingly, although baseline CF-PWV and
the decrease in CF-PWV over 3 months are similar in our study to the study
by Utescu et al, our present study showed that as markers of arterial stiffness,
both CF-PWV and AIx were significantly reduced 2 weeks postoperatively
and it persisted for 3 months afterwards (see chapter 6). One of the crucial
differences between the two studies is that none of our patients were
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commenced on haemodialysis treatment before the last study session. In
contrast Utescu et al reported that 52% of their participants were already
receiving HD at the beginning of the study and this increased to 71% at the
end of the study. Haemodialysis per se has been reported to affect both AIx
and PWV measurements significantly160-162. Recognizing this fact, we
deliberately designed our study to avoid potential effects of haemodialysis on
arterial stiffness, haemodynamics and body composition parameters. It is also
widely recognized that although PWV and AIx are two different
measurements of arterial stiffness, they are not interchangeable or
superimposable160. These important factors could well explain the difference
in AIx trend between the two studies.
Although assuming that AVF creation affecting the structure of the arterial
wall in such as short period is less likely and out there to be proven, it seems
that reduction in arterial stiffness parameters is largely associated with
reduction in the BPs. Indeed when we closely examined the relationship
between the change in CF-PWV and other haemodynamic variables, to
determine if reduction in CF-PWV can be partially explained by the changes
in the other haemodynamic variables, it was determined that changes in
peripheral diastolic BP remained the most significant determinant of change
in CF-PWV contributing around 25% to the model. None of the other
haemodynamic variables including changes in SV, TPR and HR contributed
significantly. This finding was also very similar to findings by Utescu et al.
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As arterial stiffness has been previously demonstrated to be associated with
cardiovascular risk factors and cardiovascular diseases in pre dialysis
population 163, we hypothesize that this reduction in CF-PWV may well
contribute to improved outcome in patients who have native AVF compared to
other types of dialysis access.
5.5.3 Conclusions
This study shows that AVF creation is associated with significant reduction in
arterial stiffness and blood pressures two weeks postoperatively. The
reduction in CF-PWV is associated but not completely explained by reduction
in blood pressure.
These described changes could be beneficial in longer term and could well
contribute; at least partially; to lower all cause and cardiovascular mortality in
CKD patients with AVF as vascular access compared to those with other
types of access for dialysis.
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Chapter 6
Longer term haemodynamic consequences of AVF
creation
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6 Results: Longer term haemodynamic consequences of AVF creation
6.1 Introduction
The data contained in the previous chapters demonstrates that AVF creation
is associated with acute significant changes in systemic haemodynamics,
myocardial contractile function, arterial stiffness and microcirculation reserve.
The longer term consequences of AVF formation have not been studied in
great detail previously and unfortunately, little is known about if effects of AVF
creation contribute to better survival in dialysis CKD population. What is
known though is that CKD patients who dialyse through a native AV fistula
have reduced all cause mortality compared to others dialysing through AV
graft and, even worse through tunnel venous catheters164; however; beside
reducing infection rate, it is still unknown if there are other factors contributing
to improved survival in patients with AVFs.
Reasons for paucity of studies looking into longer term effects of AVF creation
could be the fact that patients who had AVF created went onto dialysis sooner
which is associated with significant haemodynamics and body composition
alteration itself and secondly, rate of fistula failure and complications
increases as it is utilised for dialysis, rendering longer term follow up studies
rather complicated and difficult to design.
This part of the study was designed to investigate the longer term (up to 3
months) consequences related to AVF creation. It was designed as an
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integral part of the original research study aiming to investigate both acute
and longer term effect of AVF creation prior to patients starting dialysis.
6.2 Methods
6.2.1 Patients
Recruitment of patients are covered in chapter 4, section 4.2.1. Of the initial
30 patients who had successful AVF created, 21 patients consented for the 3
months follow up study. Patients who were censored included those who had
died (n=2), patients who started haemodialysis (n=3) and patients who
declined to participate in further investigations (n=4). Patients who did not
have successful AVFs were not entered into the 3 months follow up session.
6.2.2 Study protocol
3 months postoperatively, patients were approached to verbally confirm their
consent to stay in the study.
As near to 3 months as practical, patients underwent an identical study
session to the ones at the baseline and 2 weeks postoperatively. Their
medical history, progression of CKD, start date for dialysis and drug history
was reviewed and compared with the medical notes.
During 3 months follow up session, the following variables were collected:
? Haemodynamics including CO, HR, TPR and SV.
? Arterial stiffness: CF-PWV and AIx.
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? Echocardiography: M-mode and two dimensional two and four
chamber views
? Doppler ultrasound: to measure vessels diameter and AVF flow.
? Bioimpedence analysis: measuring body composition and hydration
status.
Primary end point was to assess the change in arterial stiffness measured
by CF-PWV. We already have demonstrated that CF-PWV is reduced
significantly 2 weeks after AVF creation. The aim was to determine if this
reduction was sustainable or reversible. In addition, we sought to identify
the consequences of AVF creation on left ventricular ejection fraction,
blood pressures and cardiac output after 3 months as secondary end
points.
6.2.3 Follow up collection of study data
Haemodynamic, echocardiographic, Doppler, arterial stiffness, body
composition and blood tests data were collected similar to the previous
study sessions as outlined in chapter 4, section  4.2.2 to 4.2.4 and is not
repeated here.
6.3 Statistical analysis
Power of the study and the tests used in statistical analysis are all
described in chapter 4, section 4.3 and chapter 5, section 5.3. The 3
months follow up session was powered to 80% to detect a change of 1m/s
in CF-PWV compared to the baseline with a significant level of 5%. This
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was based on the previous studies conducted in our centre which
demonstrated average CF-PWV amongst pre dialysis CKD patients to be
9±1.6 m/s.
6.4 Results
6.4.1 Baseline characteristics
Patient ?s demographics and cardiovascular risk factors are listed in table
6.1.
Parameter Patients (n=21)
Age(years) 69±9.5
Gender(male:female) 12:9
BMI 29±6.7
Ischemic heart disease 33%
Diabetes 33%
Hypertension 71%
Dyslipidaemia 71%
Smoking 57%
ACE inhibitors/ARB 71%
Pre eGFR (ml/min) 17±4
Albumin (g/l) 36±4
Hb (g/l) 11.4±1.4
Table 6.1 Demographics, CV risk factors and biochemical profile of the 3 months
follow up participants.
93
6.4.2 Systemic haemodynamics and arterial stiffness
Preoperative, 2 weeks postoperative and the 3 month follow up
measurements for the haemodynamic and arterial stiffness parameters are
listed in table 6.2.
Parameters Preoperative
2 weeks
postoperative
3 months
postoperative
Peripheral SBP 140±26 132±23 132±20
Peripheral DBP 75±12 66±11 63±10
Central SBP 130±24 120±22 120±21
Central DBP 73±12 66±11 64±11
Pulse pressure 57±17 55±17 56±17
CF-PWV (m/s) 12.45±2.6 10.8±2.4 11.0±2.8
AIx% 22±10 19±10 20±10
SV (ml) 115±32 120±40 126±37
HR (bpm) 60±12 63±10 62±10
CO (l/min) 6.3±1.4 6.9±1.2 7.3±1.3
TPR (mmHg.sec/ml) 1.0±0.23 0.84±0.20 0.8±0.15
EF (%) 45±14 51±12 53±11
Table 6.2 Preoperative, 2 weeks postoperative and the 3 month follow up
measurements for the haemodynamics, left ventricular function and arterial stiffness
parameters.
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It can be concluded that the initial changes which was recorded 2 weeks
postoperatively largely remains in the cohort with successful AVF formation
even after 3 months. For instance, on comparing CF-PWV, 2 weeks and three
months postoperatively, it did not change significantly (0.2±1.7 m/sec, p=0.7,
figure 6.1). It can also be appreciated that both peripheral systolic and
diastolic BP did not change (-0.2±16 mmHg, p=0.9 and -2±8 mmHg, p=0.7
respectively).
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Figure 6.1 Carotid femoral pulse wave velocity (CF-PWV) 2 weeks and 3 months
postoperatively.
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Comparing the haemodynamic data between 2 weeks postoperative and 3
months postoperative readings, stroke volume  (5.6±34 ml, p=0.5), HR (-2±7
bpm, p=0.3), TPR (-0.04±0.2, mmHg.sec /ml) and CO (0.4±1.8 l/min, p=0.36)
did not change significantly.
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6.4.3 Left ventricular ejection fraction
There is progressive increase in mean EF from preoperative measurements
(table 6.2 and figure 6.1).  Measurements taken 3 months postoperatively did
not show significant change in the EF (3±7%, p=0.124) compared to 2 weeks
postoperatively. None of the patients developed clinically overt high-output
cardiac failure following the access operation.
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Figure 6.2 Left ventricular ejection fraction (EF) 2 weeks and 3 months
postoperatively.
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6.4.4 AVF Doppler ultrasound measurements
Preoperative, 2 weeks postoperative and 3 months follow up Doppler
ultrasound measurements for the relevant blood vessels measurements
(artery supplying the AVF and the draining vein), arterial and fistula blood flow
are listed in table 6.3.
Parameters Preoperative
2 weeks
postoperative
3 months
postoperative
Artery diameter (mm) 43±11 51±15 61±14
Acces vein 38±11 - -
AVF diameter (mm) - 66±17 83±21
Arterial blood flow
(ml/min)
72±41 742±578 1176±603
AVF blood flow (ml/min) - 1135±600 1652±941
Table 6.3 Doppler ultrasound measurements of diameter and blood flow in the AVF
and the supplying vessels preoperatively, 2 weeks and 3 months postoperatively.
6.4.5 Body composition and laboratory data
There were no significant changes in total body water (intra and extra cellular
water) and soft tissue composition after 3 months of AVF formation. Renal
function as measured by eGFR was stable (17±5 ml/min) and comparable to
preoperative (16±4 ml/min) and 2 weeks postoperative measurements (16±5
ml/min).
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6.5 Discussion
This results chapter demonstrate for the first time that the AVF creation is
associated with haemodynamic changes which persist for up to 3 months
postoperatively.  In the previous chapters we described the acute
haemodynamic consequences of AVF creation which included increase in
HR, SV and CO and reduction in TPR and BPs. Furthermore, AVF creation
resulted in significant reduction in arterial stiffness and increase in left
ventricular EF.
This is the first study to prospectively investigate the observed effects in detail
on arterial stiffness and other cardiovascular structure and function and follow
up the same cohort for up to 3 months. Previous studies varied in their follow
up periods from days140 147 to the maximum of 6 weeks89 with small number of
participant (n=9-17) or only focusing on studying a limited number of variables
at a time. Furthermore, not all of the studies investigated CKD patients in
predialysis stages. Uniquely, we have investigated the changes in systemic
haemodynamics specifically in pre-dialysis population, without many of the
confounders that would be involved in using a dialysis based population
(changing volume status, resolution of uraemia, medication changes etc.). It
has to be noted that these comparison studies were done on a smaller cohort
of patients (n=21) compared to the original study.
Blood pressure remained lower than pre dialysis readings as were CF-PWV
and AIx. The slight increase in CF-PWV and AIx may be attributed to natural
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progression of disease in CKD patients; however; the changes were not
statistically significant.
There was also slight increase in CO (0.4±1.8 l/min, p=0.36) and left
ventricular ejection fraction (3±7%, p=0.124) but again they did not reach
statistical significance.
The view that higher flow within the AVF is associated with high output
cardiac failure is widely held. However this assertion has not been previously
tested in prospective rigorous study. As mentioned previously, all patients
who had a successful AVF formed showed an increase in their CO, however
there did not appear to be any relationship between higher Qa values and
CO. There was no clinical evidence of cardiac decompensation, with no
change in total or ECW water in any of the patients studied.
Echocardiography data demonstrated that even two weeks postoperatively,
there was a significant increase in EF.  This is similar to changes noted in
previous studies140 147.  The observed change in EF continued to be persistent
up to three months postoperatively when the vascular access had matured.
100
6.5.2 Conclusions
Formation of an AVF resulted in a significant and persistent reduction in BP
and arterial stiffness. There was increased HR and SV and reduced TPR. As
a result, CO increased. Left ventricular EF also increased and this increase
persisted up to 3 months postoperatively.
Overall the longer term post AVF adaptations might be characterised as
potentially beneficial and this could well contribute to reduction in all cause
and cardiovascular mortality in this group of patients compared to patients
with other types of vascular access.
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Chapter 7
Effects of AVF creation on local and systemic
microcirculation
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7 Results: effects of AVF creation on local and systemic
microcirculation
7.1 Introduction
Little is known about the effect of AVF creation on local and systematic
microcirculation. This chapter describes a study designed to characterise this
in  a cohort of predialysis population.
Endothelium is the largest organ in the body. It forms an interface between
blood stream and vascular smooth muscle cell in the vessel wall. It responds
to mechanical factor such as shear stress and pressure and humoral factors.
Amongst its important functions are regulation of
vasodilatation/vasoconstriction response, antiinflammatory and antithrombotic
properties. Therefore, endothelial dysfunction is characterised by impairment
in vasodilatory response and a proinflammatory and prothrombotic state.
Endothelial dysfunction has been associated with large number of
cardiovascular risk factors and diseases including diabetes mellitus165-167,
hypertension168-172, ischaemic heart disease, peripheral vascular disease,
hypercholesterolemia,  hyperhomocystinaemia and chronic kidney disease173-
174.
Several mechanisms have been proposed for endothelial dysfunction in these
conditions including reduced bioavailability of nitric oxide (NO), increased
asymmetric dimethylarginine (ADMA), increased oxidative stress, insulin
resistance and accumulation of advanced glycation end product (AGE).
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Defective microcirculatory perfusion of the myocardium in combination with
the dialysis induced circulatory stress appears to be a significant component
of the prevailing pathophysiological processes increasing the risk of
myocardial hypoperfusion. Studies of myocardial blood flow during HD in
patients with normal coronary angiograms152 and dialysis induced cardiac
segmental ischaemia in children on haemodialysis153, have highlighted the
existence of demand myocardial ischaemia in the absence of atheromatous
large vessel coronary artery disease .
The assessment of subcutaneous dermal capillaries is a primary method for
the assessment of the microcirculation.  These vessels are representative of
the microvascular supply to the heart 113 and kidneys 114. This might allow
study of the relatively accessible microcirculation to provide a window to
critical central vascular beds. Abnormalities of endothelial function
demonstrated using LDF can provide additional quantification of CV risk when
used in conjunction with conventional risk scores 115. LDF also appears able
to document endothelial cell dysfunction in ESRF patients prior to clinical
evidence of cardiovascular disease or diabetes mellitus 175.
Although some data are available on microcirculatory function in HD patients
to date there are no studies examining the impact of vascular access
formation either in the subtended distal limb or potential systemic effects that
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might be important in the pathophysiology of the aggravated cardiovascular
risk that patients on HD are subjected to.
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7.2 Methods
7.2.1 Patients
Recruitment of patients are covered in chapter 4, section 4.2.1. and will not
be discussed here again.
On the study days, patients were asked to refrain from taking caffeine
containing drinks or smoke for at least 12 hours, and not to take their
vasoactive medications for at least 24 hours before the study. Patients were
allowed to acclimatise in the sitting position for at least 20 minutes prior to
starting the study. All studies were done in a temperature and light controlled
room (23°C).
All the studies were done on the palmar surface of forearm bilaterally. The
arm was positioned at heart level and immobilized using a vacuum pillow
containing polyurethane beads, which moulds to the shape of the arm
(Germa, Sweden). To standardise the measurements further, two areas on
the volar aspect of forearm were chosen, one for each drug. These were
gently cleaned with alcohol wipe and sufficient time was allowed for the
alcohol to fully evaporate. Locations on the forearm were chosen to avoid
large vessels, pigmentations, scars and uneven surfaces. The drug delivery
electrode chamber for acetylcholine iontophoresis was attached 5 cm below
the elbow line and for sodium nitroprusside 10cm below the elbow line. The
electrode chambers were covered with a plastic top to pr
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drugs. Baseline images, during which no drug was administered, were
required for 90s prior to starting iontophoresis.
7.2.2 Iontophoresis
Anodal iontophoresis was used to deliver Ach and cathodal iontophoresis for
SNP delivery using a battery powered iontophoresis controller (PeriIont 382,
Perimed AB, Stockholm, Sweden). DC current of 0.02 mA was used for 420
seconds for iontophoresing both drugs.  This protocol was used to specifically
minimise non-specific vasodilatation by limiting the current density and charge
density, and at the same time allowing enough time to obtain a maximum
blood flow response to both drugs176.
7.2.3 Laser Doppler perfusion imaging
For details of this technique, please see chapter 3, section 3.8. A laser
Doppler perfusion imager (PIM II®, Perimed, Sweden) was used to measure
changes in skin perfusion during iontophoresis. Particular attention was given
to making sure that the distance between the head of the laser Doppler
imager and the skin was constant at 15cm, and that it was parallel to the skin
surface in all experiments.
Data was captured using the LDPIwin Version 2.6 software (Perimed AB,
Sweden).  The perfusion response is measured in arbitrary perfusion units
(PU).  As the PU values are
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not absolute blood flow, the percentage change from baseline and the time
taken to reach the maximum response were recorded.
Our group have previously shown the intra-individual coefficient of variation of
this technique to be 18.7% for ACh and 15.2% for SNP177. Acetylcholine
(Ach) and sodium nitroprusside (SNP) were used as endothelial dependant
(ED) and non endothelial dependant (NED) vasodilators respectively. These
were dissolved in deionised water to give a final concentration of 1%.
7.2.4 Statistical Analysis
Results are expressed as mean ± SD if parametric or median (interquartile
range, IQR) if non-parametric unless otherwise stated. For comparing pre-
and post operative data, either paired t-test or Wilcoxon rank sum test was
used depending on normality of the distribution. An alpha error at P<0.05 was
judged to be significant. All statistical analysis was performed with the use of
the SPSS software package, version 12 (SPSS Inc., Chicago, IL, USA).
7.3 Results
7.3.1 Baseline characteristics
30/43 patients had a successful AVF operation (5 wrist and 25 elbow).
Patients with failed AVF (13/43) procedures were utilised as sham operated
controls. All patients had an end-to-side anastomosis and the operations were
done as a day case under local anaesthetic. One patient died before
attending the second study session. Two patients who had an unsuccessful
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AVF operation first time, were re-recruited and consequently had a successful
AVF formed.
Demographics, biochemical and cardiovascular risk factors of the study
participants according to their operation outcome is discussed in chapter 4,
section 4.4.1 and table 4.1.
Patients with failed AVF (13/43) procedures were utilised as sham operated
controls. For the haemodynamic profile of both groups pre and
postoperatively, please refer to table 4.2 (page68).
109
7.3.2 Baseline measurements
7.3.2.1 Patients with successful AVF operation
Preoperatively, in the successful group, baseline perfusion measurements in
the forearm designated for AVF formation were NED 0.67±0.1 PU, and ED
0.62±0.07 PU. In non AVF forearm these figures were NED 0.64±0.08 PU
and ED 0.6±0.05 PU.
Postoperatively, baseline readings in the AVF forearm of the successful group
were NED 0.68±0.1 PU and ED 0.66±0.1 PU. In non AVF forearm these
figures were NED 0.67±0.1 PU and ED 0.63±0.09 PU.
7.3.2.2 Patients with unsuccessful AVF operation
Preoperatively, baseline perfusion measurements in the forearm designated
for AVF formation were NED 0.69±0.09 PU and ED 0.62±0.1 PU. In the non
AVF forearm these figures were NED 0.66±0.1 PU and ED 0.59±0.1 PU.
Postoperatively, baseline readings in the attempted AVF forearm were NED
0.68±0.1 PU, ED 0.65±0.2 PU and in non AVF forearm NED 0.63±0.1 PU and
ED 0.57±0.06 PU.
With the exception of baseline measurement for postoperative ED
vasodilatation (p=0.049) in the non AVF forearm, there was no other
statistically significant difference in the mean perfusion in baseline
measurements between the successful and unsuccessful group both pre and
postoperatively.
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7.3.3 Maximum vasodilatation response to iontophoresis
7.3.3.1 Patients with successful AVF operation
Preoperatively, percentage of change from baseline perfusion in response to
maximum vasodilatation in AVF forearm were NED 1.13±0.28 PU (68±33%)
and ED 1.34± 0.34 PU (114±47%). For non AVF forearm these figures were
NED 1.2± 0.27 PU (92±49%) and ED 1.32± 0.3 PU (118±54%).
Postoperatively, percentage of change from baseline perfusion in response to
maximum vasodilatation in AVF forearm for NED 1.07± 0.3 PU (58±40%) and
for ED 1.2± 0.3 PU (84±43%). For non AVF forearm, NED was 1.11± 0.3 PU
(69±41%) and ED 1.27± 0.3 PU (105±65).
7.3.3.2 Patients with unsuccessful AVF operation
Percentage of change from baseline perfusion in response to maximum
vasodilatation in the forearm designated for AVF formation were NED 1.28±
0.3 PU (88±64%) and ED 1.45± 0.4 PU (140±76%). In the non AVF forearm
these figures were NED 1.27± 0.3 PU (93±45%) and ED 1.47± 0.4 PU
(158±90%).
Comparing the maximum vasodilatation between successful and
unsuccessful groups pre operatively, there was no significant difference in
either forearms for both ED and NED vasodilatation.
Postoperatively, percentage of change from baseline perfusion in the forearm
with attempted AVF formation were NED 1.28± 0.3 PU (89±43%) and ED
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1.56± 0.6 PU (135±46%). For non AVF forearm these figures were NED
1.34±0.33 PU (114±59%) and ED 1.33± 0.4 PU (133±67%).
When comparing maximum vasodilatation between the successful and
unsuccessful groups postoperatively, maximum response to ED
vasodilatation was significantly different (p=0.02) in the AVF forearm. In
addition, postoperative maximum response to NED vasodilatation was
significantly different (p=0.01) in the non AVF forearm between the two
groups.
The time required to achieve maximum vasodilatation was not statistically
different between the groups for corresponding tests in the corresponding
limbs either pre or postoperatively.
When pre and postoperative measurements are compared, a reduction in
maximum ED vasodilatation response to Ach was observed in the fistula
forearm in patients with successful AVF formation (-36±46%, p<0.001, see
figure7.1). This did not change significantly in the non fistula arm of the
successful AVF group.
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Figure 7.1 Percentage reduction in mean perfusion in AVF arm in successful group
in response to Ach iontophoresis.
Similarly, maximum NED vasodilatation response to SNP was reduced in the
non fistula forearm in patients who had a successful AVF formation (-23±40%,
p=0.01, see figure 7.2). Again, this change was not noted in the AVF forearm.
Patients who had unsuccessful AVF operation did not show any statistically
significant change in their ED and NED vasodilatation response between pre
and post operative measurements.
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Figure 7.2. Percentage reduction in mean perfusion in non AVF arm in successful
group in response to SNP iontophoresis.
We also looked into the effect of the AVF location on the described results.
We subdivided the patients who had successful AVF created according to the
location of their AVF into wrist and elbow group. There was no statistically
significant difference in the baseline and maximum vasodilatation response
pre and postoperatively between wrist and elbow AVFs.
7.4 Discussion
This is the first study to prospectively investigate the microvascular effect of
AVF formation locally and systematically. The utilisation of patients with
primary technical failure provides the opportunity to study those effects
controlled against a group of patients undergoing the same progression of
uraemic factors, but without a formed shunt.
We have demonstrated for the first time that AVF formation is associated with
reduction in endothelial dependant vasodilatation in the fistula forearm.
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Furthermore, it had systemic effect by reducing non endothelial dependant
vasodilatation in the contralateral forearm.
The presence of endothelial dysfunction is well described in patients with
different stages of CKD. Thambyrajah et al.173 found that in comparison to
healthy controls, patients with various abnormal glomerular filtration rate
showed abnormality of endothelial dependant but not non endothelial
dependant vasodilatation even in absence of atherosclerotic cardiovascular
disease.  Farkas et al. 178 showed impaired ED and NED vasodilatation in
hypertensive haemodialysis patients using laser Doppler flowmetry and
iontophoresis of Ach and SNP. Their findings were also supported by
alteration in levels of endothelial function biomarkers in this group of patient.
We have demonstrated for the first time that AVF formation affects
microcirculation function both locally and systematically. Alteration in pressure
and shear stress (the frictional force generated from blood flow on the vessel
wall) on vascular endothelium layer can contribute to these changes. Change
in shear stress has been associated with modifying physiological and
pathological processes associated with endothelium such as
vasodilatation/vasoconstriction, endothelial cell proliferation, inflammation and
thrombosis. It is well recognised that in normal blood vessels, the shear
stress generated by normal laminar flow results in continuous production of
nitric oxide (NO) from the endothelial cells which in turn protects the cells
from apoptosis179-180. Furthermore, it has been proposed that sites with
turbulent blood flow and altered shear stress are associated with increased
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cell turnover181-182. The association between abnormal turbulent blood flow
and change in endothelial cell shape and function has also been well
described183-186.  Certainly, creation of an AVF generates turbulent blood flow
in local circulation. It will also bypass the normal arteriole-capillary-veniole
blood flow pathway and generates a shunt with flow rates varying between
500ml/min to even more than 3000ml/min. Furthermore, it has been shown
that both wall shear stress and vessels diameter increased suddenly in the
proximal arteries after AVF formation and this increase in wall shear stress
remained unchanged 1 year after the operation187.
Moreover, we have already demonstrated that AVF creation is associated
with marked functional and structural cardiovascular changes188. These
changes included increase in cardiac output, reduced total peripheral
resistance, reduced systolic and diastolic blood pressures, increased ejection
fraction and a reduction in the markers of arterial stiffness.
We propose that the observed changes in microcirculation, both locally and
systemically are resulting from firstly the changes to function and structure of
the endothelium induced by alteration in the vascular shear stress locally and
secondly wider systemic haemodynamic effects caused by the AVF
formation.
The limitations of this study are small sample size and lack of concurrent
measurement of wall shear stress. This is the first study looking prospectively
into microcirculatory changes/endothelial function in this group of patients.
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For the sake of time and decreasing the demand on the participants,
measuring wall shear stress was not performed
It is currently not known how these changes in microcirculation affect other
organs blood flow and pathophysiology. We have identified that both systemic
and local vasodilatation responses change after AVF creation. From our
study, one interesting negative finding was lack of correlation between
baseline and maximum vasodilatation and the likelihood of an AVF formation
being successful or not. However; endothelial dysfunction may well contribute
to further impairment of already diseased peripheral vessels in CKD patients
and may well play an important role in future local vascular complications and
AVF failure. Certainly further prospective studies are required to explore the
relationship between microcirculation and fistula dysfunction.
Systemically, it is currently unknown how this reduction in NED vasodilatation
secondary to AVF formation affects cardiovascular performance and
prognosis in this group of patients.  Previous studies have indicated that peak
vasodilatation response was significantly reduced in a cohort of end stage
renal disease patients at high cardiovascular risk measured using
Framingham and Cardiorisk scores115.  It is not currently known if this further
reduction in vasodilatation response secondary to AVF formation is
associated with an increase in cardiovascular mortality and morbidity and
again it requires further study.
Given such a high rate of cardiovascular mortality and morbidity in our CKD
patients, studying these effects will certainly increase our understanding
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about the scope of problems encountered by patients, may help in developing
new therapies to improve outcome in CKD.
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Chapter 8
Higher arteriovenous fistulae blood flows are associated
with a lower level of dialysis induced cardiac injury
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8 Results: higher arteriovenous fistula blood flow are associated with a
lower level of dialysis induced cardiac injury
8.1 Introduction
Very high fistula flows (>1500ml/min) are generally recognised as being
capable of inducing a high output state and precipitating cardiac failure89 139.
However, high fistula blood flow (Qa) does not seem to predispose to
increase mortality and indeed a reduced Qa might be associated with
decreased survival189.
It is well recognised that dialysis patients display hugely elevated rates of
cardiac mortality. It is also becoming appreciated that this rate of
cardiovascular attrition is not driven by the same variety of risk factors, or
pathophysiological processes that are important in the general population142.
Cardiac failure develops in as many as 25-50% of HD patients and confers a
dramatic reduction in probability of survival143. In addition, a significant
percentage of cardiac mortality is due to sudden death190-191. Abnormal
ventricular morphology and function appear to be major determinants of
cardiovascular outcome in this patient group192.
It has long been suspected that myocardial ischaemia may be precipitated by
HD. There have been a variety of studies confirming dialysis induced
myocardial ischaemia192-193. In conjunction with this, HD patients are
particularly susceptible to myocardial ischaemia. In addition to the high
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prevalence of coronary artery atheroma144, diabetic dialysis patients have
been shown to have a reduced coronary flow reserve (CFR) in the absence of
coronary vessel lesions145. Haemodialysis patients characteristically also
exhibit left ventricular hypertrophy (LVH), reduced peripheral arterial
compliance, impaired microcirculation107 194 and ineffective vasoregulation (in
the face of HD coupled with ultrafiltration). All of these factors predispose to
demand myocardial ischaemia.
In patients with coronary artery disease, but without CKD, transient
myocardial ischaemia may lead to left ventricular dysfunction that can persist
after the return of normal perfusion. This prolonged dysfunction is known as
myocardial stunning195. Repetitive episodes of ischaemia can be cumulative
and have been shown to lead to prolonged left ventricular dysfunction.
Myocardial stunning is thought to be a causative mechanism for heart failure.
We have demonstrated that the phenomenon of dialysis induced cardiac
injury is common, occurring in around 60% of patients studied, and is
associated with global and segmental significant reductions in myocardial
blood flow152 leading to a reduction in the left ventricular ejection fraction,
increased arrhythmias and decreased survival154 196. Dialysis induced
myocardial stunning is partially abrogatable by modification of the dialysis
process to improve the systemic haemodynamic response to treatment197-198.
The aim of this study was to examine the effect of local AVF blood flow rate
on dialysis induced, ischaemic based, reversible cardiac injury. Thus
determining whether or not AVF formation was likely to favour the
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development of demand myocardial ischaemia, or potentially provide a
degree of cardio-protection.
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8.2 Methods
8.2.1 Patients
Patients within this study represent the 50 patients with mature fully functional
native vascular access within a larger group of seventy prevalent HD patients.
These were recruited for a 12-month observational cohort study from a single
hospital based haemodialysis unit. Patients were excluded if they had pre-
existing severe LV systolic dysfunction (NYHA IV) or inadequate
echocardiographical windows to obtain images of sufficient quality. Only one
patient was excluded on this basis. There were no other significant exclusion
criteria. All patient ages and primary aetiologies of CKD were included.
All patients were on thrice weekly dialysis lasting four hours. Patients were
divided into tertiles based on Qa value (summary of patient characteristics is
given in table 8.1).
All patients gave informed consent before the study start, and ethical approval
for the project was granted by Derbyshire Local Research Ethics Committee.
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Qa<500 ml/min
Qa500-1000
ml/min
Qa>1000
ml/min
P value
Qa (ml/min)
291±101 739±130 1265±221
<0.001
(between all
values)
N 19 15 16
Age (years) 64.1 ± 13.4 62.3 ± 11.2 65.1 ± 11.9 Ns
Dialysis vintage
(months)
46.8 ± 28.7 47.6 ± 24.3 50.6 ± 31.3 Ns
Sex (m:f) 14:5 9:6 9:7 Ns
Diabetic (%) 21 33 25 Ns
Previous CV
Co-morbidities
(%)
16 38 31 Ns
Hb (g/dl) 10.8± 0.6 10.6± 0.4 11.1± 0.6 Ns
Corrected
Calcium (mmol/l)
2.39± 0.13 2.44± 0.11 2.41± 0.12 Ns
Phosphate
(mmol/l)
1.59± 0.9 1.61± 0.9 1.60± 0.08 Ns
Albumin (g/l) 33.6± 5 34.1± 4.9 34.3± 5 Ns
cTnT (µg/l) 0.12±0.02 0.09±0.03 0.03±0.01 0.01
Kt/VUREA 1.48± 0.3 1.46± 0.4 1.52± 0.3 Ns
Interdialytic
weight gain (kg)
1.65± 0.2 1.72± 0.3 1.49± 0.2 Ns
Systolic BP
(mmHg)
149 ±28 144 ±24 138 ±23 Ns
Diastolic BP
(mmHg)
80 ±15 77 ±12 76 ±13 Ns
Pulse pressure
(mmHg)
67 ±21 65 ±23 64 ±21 Ns
Table 8.1 Description of the study subjects categorised by Qa value
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8.2.2 Study design
Patients underwent Qa measurement 30 minutes into the first HD session
after the short interdialytic interval. Measurement of QA was performed
utilising a non operator dependant technique based on dual measurement of
ionic dialysance and flow reversal (using specific crossed line extensions and
clamps, to avoid the need to disconnect blood lines)199. All Qa studies were
performed within one week of the echo based study visit. This is to avoid the
possibility that the Qa measurement procedure (with period of fixed UF rate)
did not impact on any possible observed changes on myocardial stunning.
Blood samples were collected before each session in lithium heparin and
EDTA tubes, and biochemical analysis performed on a multichannel
autoanalyser. Cardiac troponin-T (cTnT) analysis was performed using a third
generation electrochemiluminescence assay (Roche diagnostics, Lewes, UK).
8.2.3 Echocardiography
Two-dimensional echocardiography was performed serially throughout
dialysis sessions by using commercially available equipment (1.5-3.6 MHz 3S
probe, Vivid 3®, GE medical systems, Sonigen, Germany). A single
experienced technician carried out all measurements with the patients in the
left lateral position. Images were recorded before starting dialysis (baseline),
and 240 minutes during dialysis. Standard apical two-chamber and four-
chamber views (to visualize the LV endocardial border in two planes at 90° to
each other) were digitally recorded onto a compact disc for offline analysis.
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Digital images were subsequently transferred and analysed by using a
personal computer ?based digitising program (CMS-View, DICOM review
station and Echo-CMS; MEDIS, Leiden, The Netherlands), as previously
described 200. Three consecutive heartbeats were analysed for each time
point (extra-systolic beats were excluded). Endocardial borders (excluding
papillary muscles) were traced semi-automatically for each video frame of the
3-beat sequence, and any anomalies were corrected for manually. Maximal
displacement of the endocardial border from a centre point then was
measured over each of 100 chords around the left ventricular (LV) wall,
corrected for end-diastolic LV circumference, and expressed as percentage of
shortening fraction (SF). Severity of dialysis induced myocardial stunning was
represented by the number of segments that displayed significant reduction in
SF, and the mean cumulative reduction in SF in those areas.
Each apical view was divided into 5 segments, and SF for the chords in each
segment was averaged so that 10 regions of the left ventricle were assessed
at each time. New regional wall motion abnormalities (RWMA) were defined
as segments that showed a decline in SF greater than 20% from baseline.
Left ventricular ejection fraction (LVEF) was calculated using LV volumes at
end systole and end diastole, measured by the biplane disk method. LV mass
index (LVMI) was calculated from each patient ?s original baseline images
using the Devereux formula corrected for height.
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8.2.4 Haemodialysis details
Dialysis was performed using Hospal Integra monitors (Hospal, Mirandola,
Italy) using low-flux polysulfone dialysers, either 1.8 or 2.0m2, per individual
patients ? usual prescriptions (LOPS 18/20; Braun Medical Ltd, Sheffield, UK).
Dialysate fluid contained sodium, 138 mmol/L, potassium 1 mmol/L, calcium
1.25 mmol/L, magnesium 5 mmol/L, bicarbonate 32 mmol/L, glucose 1 g/L,
and acetate 3 mmol/L.
All treatments were of four hours ? duration, and anticoagulation was with
unfractionated heparin. Dialysate flow was 500 mL/min, and dialysate
temperature was set at 36.5°C. For each session, net fluid removal was set
on an individual basis according to ideal dry weight. Blood pump speed varied
between 250 and 450 mL/min, depending on the patient ?s vascular access.
8.3 Statistical analysis
Results are expressed as mean ± SD for parametric data or median
(interquartile range, IQR). Echocardiographic, BP and haemodynamic data
were analysed using one-way analysis of variance (ANOVA) with a design for
repeated measures and Bonferroni ?s test to correct for multiple comparisons.
Chi squared tests were used to compare categorical data.  For other data,
either the paired t-test or Wilcoxon rank sum test was used depending on
normality of the distribution. An alpha error at P<0.05 was judged to be
significant.
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8.4 Results
8.4.1 Qa values and patient characteristics
The patients were divided into three groups on the basis of their Qa values.
The values were based upon current K/DOQI recommendations for vascular
access monitoring (concerning recommendations for enhanced access
monitoring and direct vascular imaging). The mean Qa in the lower access
flow group was 291±101 ml/min vs. 739±130 ml/min and 1265±221 ml/min in
the higher flow groups (p= 0.001 between all values). Even in the highest flow
group the maximum Qa was 1881 ml/min. 65% of AVFs were radiocephalic,
with the balance being brachiocephalic (apart from two AVF utilising the
basilic vein). There were no differences in the distribution of AVF type
between the patient groups. 90% of these AVFs had been formed with a
common approach of local anaesthesia and a side to side anastamosis, with
no formal surgical attempt at flow assessment or limitation. All AVFs had
been in situ for at least six months.
There were no statistically significant differences between the patients in
these groups for any of the routine patient descriptors, standard haematology/
biochemical testing, delivery of dialysis, nutrition (serum albumin), blood
pressure (BP) or pulse pressure (summarised in table 8.1). Detailed study of
intradialytic blood pressure was beyond the scope of this study, but there
were no statistically significant differences between pre and post dialysis
systolic or diastolic BP.
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8.4.2 Echocardiographic assessment
There were no significant differences in systolic function, as assessed by
resting LVEF between the three groups (table 8.2). Patients with higher Qa ?s
displayed a trend towards lower LVMI (82.1±17, 78±18 and 72±21 ml/min
respectively for the low to high Qa patient groups). This did not reach
statistical significance (p = 0.065 between Qa <500 ml/min and >1000 ml/min
patient groups).
Qa < 500
ml/min
Qa 500-1000
ml/min
Qa >1000
ml/min
P value
LVEF (%)
56± 12.1 54± 11.7 56± 11.4 Ns
LVMI (g/m2.7) 82.1±17 78±18 72±21 Ns
Number of
segments
significant
reduction in SF
(per patient)
3.8± 2.6 3.4± 2.1 2.3± 2.0 Ns
Sum of
reduction in
fractional
shortening in
effected
segments (per
patient)
-187± 161 ? -160± 102 -101± 102 ? 0.02
Table 8.2 Echocardiographic results for patients divided into tertiles on the basis of
Qa.
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When considering the presence or absence of left ventricular hypertrophy,
there was a significantly lower proportion of patients when divided into two
groups (22/29 patients, 76% vs. 8/14 patients, 55% p=0.01) (figure 8.1).
    p=0.01
Figure 8.1 Proportion of patients with LVH characterised by their Qa
Patients with higher Qa AVFs were subject to significantly less dialysis
induced acute cardiac injury. This was assessed by both the number of
myocardial segments that developed a reduction in contractile function
(RWMAs), and the sum of reduction in fractional shortening in those affected
segments. Number of RWMAs induced by HD was sequentially lower in the
patient groups with higher flow AVFs (3.8± 2.6, 3.4± 2.1 and 2.3± 2.0
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respectively for the low to high Qa patient groups). This did not reach
statistical significance (p = 0.07 between Qa <500 ml/min and >1000 ml/min
patient groups).
There was however a statistically significant reduction in sum reduction in
fractional shortening in patients with higher Qa AVFs (-187± 161, -160± 102
and -101± 102% respectively for the low to high Qa patient groups, p=0.02).
These differences in function were reflected by similar differences in
biochemical evidence of cardiac injury (pre dialysis serum cTnT values
0.12±0.02, 0.09±0.03 and 0.03±0.01 µg/l respectively for the low to high Qa
patient groups). This reached a statistical significance of p=0.01 between Qa
<500 ml/min and >1000 ml/min patient groups. Differences between both
extremes and the Qa 500-1000 ml/min group were both p=0.06.
Stepwise multivariate analysis of those factors contributing to the presence of
RWMAs revealed that the following were all independent variables associated
with the development of HD-induced RWMAs: maximum reduction in SBP,
per mmHg (OR 1.3, CI 1.04-1.2, P=0.001); UF volume per litre (OR 4.2, CI
1.42-21.1, P=0.01), cTnT concentrations per μg/L (OR 1.08, 1.01-1.19,
P=0.03) and Qa with a reduction in OR for higher flow AVF vs. lower and
medium flow of 0.76 (CI 0.51-0.97, P=0.03) (Nagelkerke R2=0.48 of the model
overall). All other factors, including diabetes mellitus, albumin levels and IHD
did not enter the final analysis.
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8.5 Discussion
This study is the first to provide preliminary evidence that AVF function, and
its effect upon demand myocardial ischaemia, might play a role in the
observed improved longer term outcomes in patients receiving dialysis via
native AVFs.
There are no consistently identified factors that determine Qa within an AVF
in an individual patient. Although various studies have identified cardiac
index, AVF position, ischaemic based primary renal disease201 and systolic
blood pressure202 as potential factors, we found no significant differences in
these, or any other patient descriptive factors, between the various Qa
groups. The absolute flows within this study are in keeping with those
generally described, but with a noted absence of many very high flow AVFs
(Qa>1500 ml/min) reducing the likelihood of high output cardiac failure 203. It
did not appear that by separating patients into groups based on Qa prior to
analysing them for cardiac injury, we were generating three patient groups
likely to have a differing response to cardiac stress unrelated to AVF function.
There were no differences between the groups for overt cardiovascular
disease, age, diabetes, blood pressure or resting LVEF.
We have previously identified dialysis induced myocardial stunning as a
common consequence of HD197-198 204-205, and identified that it is associated
with a number of dialysis related factors (ultrafiltration volume and
maintenance of BP primarily). Patients in this current study, despite exhibiting
differing degrees of new RWMA development with dialysis, were not different
132
with respect to those factors. Access type and function had not been a feature
of the previous studies.  Multivariate analysis has confirmed the crucial role
played by dialysis induced relative hypotension and UF volume/rate that we
have previously reported22. In addition higher flow AVFs appear to be
independently associated with a lower degree of dialysis induced cardiac
stunning. The small numbers in these sub groups though are not ideal for
such multivariate data treatment.
We did not attempt to study the effect of not having an AVF at all largely for
logistical reasons. Within our renal service only a small proportion of patients
(10-15%) rely on central catheter access. These patients are characterised by
being new to dialysis or having severe co-morbidities or acute intercurrent
illness. The virtual absence of patients with arterio-venous grafts (AVG) within
our unit precluded inclusion of this patient group, and must be considered a
limitation of this initial study. The lack of of patients within this study with
AVGs mean that no comment can be made concerning the potential impact of
this form of vascular access.
The literature concerning the cardiovascular results of AVF formation is both
limited and short term. Although there is some evidence that formation of an
AVF might predispose to cardiac ischaemia and LVH development, there are
no data directly relating to the degree of flow in the AVF (well summarised in
review by McRae and co-authors)206. Although there are currently very few
studies directed at the systemic cardiovascular consequences of AVF
formation and function it is intriguing to speculate on what might be the
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mechanism for the observed cardio-protective effect, from a well functioning
AVF. Possibilities might include alteration of arterial stiffness (which can
regulate the likelihood of demand myocardial ischaemia207, alteration of
sympathetic over activity, reduction in either pre load or after load and the
delivery of greater amounts of oxygenated blood to the central circulation
(with modulation of central baroreflex control and coronary perfusion). The
finding that patients with higher flow AVFs appeared to have developed less
increase in LV mass suggests that alteration in arterial compliance, or
ventricular loading may indeed be involved.
Of particular interest might be the role of remote ischaemic preconditioning
(RIPC). It has been appreciated for some years that transient ischaemia of a
vulnerable organ provides a degree of protection for that organ in the face of
a further ischaemic insult. It also appears that remote ischaemia (e.g. from
intermittently cuffed limb ischaemia) results in a both a humoral and neuronal
cascade, providing protection of the heart from subsequent ischaemic
injury208 . Intermittent upper limb ischaemia has been recently demonstrated
to protect patients undergoing coronary artery bypass grafting from procedure
related cardiac ischaemic damage (as evidenced by serum cTnT levels)209.
Distal relative ischaemia from a higher flow AVF, either at rest, or during the
intermittent use of the AVF during HD, might result in a similar process and
provide a degree of RIPC for the heart.
In conclusion, this study provides initial data to suggest that a well
functioning, higher flow AVF is associated with reduced incidence of dialysis
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related cardiac ischaemia. It is consistent with the empirical clinical
observation that patients with well functioning access appear to have better
clinical outcomes, and provides additional reinforcement for current programs
promoting the use and maintenance of definitive vascular access.
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Chapter 9
Conclusions, Study Limitations and Future work
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9 Conclusions, Study Limitations and Future Work
9.1 Conclusions
CKD is a major health problem worldwide with increasing incidence and
prevalence. Cardiovascular diseases are a major cause for mortality and
morbidity in CKD patients.  It has been increasingly appreciated that the risk
factors for cardiovascular diseases in CKD patients are beyond and above
the traditional risk factors in non CKD patients. One of the important non
traditional risk factor which has been associated with increased
cardiovascular and all cause mortality in CKD population is increased arterial
stiffness. In addition to these traditional and non traditional risk factors, these
patients are exposed to complications from uraemia and dialysis treatment for
their renal failure. As dialysis population continue to grow, this excess in
mortality is becoming more of an important issue.
The type of access used to administer haemodialysis has been a
controversial subject until recent years. Large studies have shown reduced
morbidity (and hospitalisation) and mortality using native AVFs compared to
both AVF grafts and tunnelled venous lines164. The reason behind improved
survival in patients with native AVFs has always been attributed to reduced
risk of infection associated with using AVFs.  However, our results are first to
suggest that there might be other factors which could potentially contribute to
this improvement in survivals in patients with native AVFs.
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Although different, limited aspects of haemodynamic changes in response to
AVF creation has been looked into in different studies, no previous study has
looked into the effects of AVF formation on arterial stiffness. Furthermore, our
study prospectively followed up a cohort of predialysis patients immediately
after AVF formation and after allowing sometime for the AVF to mature.
Our cohort consisted of CKD 4 and 5 patients attending low clearance clinic
and were referred for AVF creation.  The success rate obtained in this cohort
generally mirrors average national success rate. One of the advantage of this
study was using patients underwent unsuccessful AVF created as sham
operated controls for comparison purposes.
Firstly, we looked into the acute effect of AVF formation on systemic
haemodynamics. We demonstrated that AVF formation is associated with
reduction in TPR, increased SV and HR. As a result of these changes, CO
significantly increased. These findings were consistent with the findings from
previous studies and only happened in patients with successful AVF s.
Furthermore; analysis of our echocardiography data confirmed an increase in
EF in patients who had successful AVF formed. There was no evidence of
acute cardiac decompensation clinically in this group of patients.
Furthermore, both systolic and diastolic BP were both reduced after a
successful operation. This was true for measurements done peripherally and
centrally using aortic pulse wave analysis.
AVF formation was also acutely associated with a marked reduction in arterial
stiffness as measured by CF-PWV and AIx.  This was in contrast to previous
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studies (n=9) measuring AIx (but not CF-PWV which is the gold standard)
reporting no significant changes during their follow up period.  More recently,
Utescu et al demonstrated that successful AVF formation was associated with
reduction in CF-PWV and mean BP and a non significant increase in AIx159.
Interestingly, although baseline CF-PWV and the decrease in CF-PWV over 3
months are similar in our study to the study by Utescu et al, our present study
showed that as markers of arterial stiffness, both CF-PWV and AIx were
significantly reduced 2 weeks postoperatively and it persisted for 3 months
afterwards. One of the crucial differences between the two studies is that
none of our patients were commenced on haemodialysis treatment before the
last study session. In contrast Utescu et al reported that 52% of their
participants were already receiving HD at the beginning of the study and this
increased to 71% at the end of the study.
As part of the analysis, we looked into the correlation between ∆PWV and
other haemodynamic variables. The reason behind this is the proposed
association between the change in vascular stiffness being caused by change
in blood pressure. A stepwise multiple regression model showed that both
changes in diastolic BP and presence of diabetes were independently
associated with reduction of CF-PWV with reduction in diastolic BP
independently contributing to 25% of the model. We suggested that although
the observed change in the blood pressure contributes to reduction in PWV,
there are other indeterminate factors largely responsible for this reduction.
This is supported by previous studies which demonstrated that the lack PWV
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reduction in response to BP reduction is an independent significant predictor
of mortality in CKD patients.
We concluded that at least during the acute stages following AVF creation,
the adaptive changes in cardiovascular physiology could be potentially
described as beneficial in this group of patients as indicative by reduction in
BP s and arterial stiffness.  It is important to mention that these acute
haemodynamic changes were observed without any noticeable change in
body water content/soft tissue composition. Renal function and haemoglobin
also remained unchanged postoperatively.
Investigating the longer term consequences of AVF formation was also
planned when the study was designed. Therefore, those patients who had
successful AVF formed and consented to undergo the second session, were
re-studied in a similar way after AVF maturation (3 months postoperatively).
We demonstrated for the first time that the adaptive changes acquired
immediately after the AVF formation, were persistent. CF-PWV and AIx both
stayed reduced compared to their preoperative values. This was also true for
the BP s which stayed low as well. Mean CO was slightly higher 3 moths
postoperatively compared to the 2 weeks postoperative values as was left
ventricular EF. Again, no patient suffered acute cardiac decompensation
clinically during the second follow up period and no significant change in body
composition, hydration status, renal function or haemoglobin was observed.
When we studied a different cohort of patients cross-sectionally, we
demonstrated that dialysis induced myocardial stunning was reduced in
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patients with higher AVF flows. These findings were consistent with the
empirical clinical observation that patients with well functioning access appear
to have better clinical outcomes. However; this study was limited by its design
and further longitudinal studies are required to ascertain the findings.
As microcirculation is an important and integral part of cardiovascular
physiology, we also looked into the acute effects of AVF creation on
microcirculatory function. Changes in vasodilatation response to
iontophoresis (both ED and NED) were measured pre and postoperatively, in
the fistula forearm and non fistula forearm.
We discovered that although baseline readings were broadly similar in both
groups for both arms, changes only happened in patients who had successful
AVF s created. Significant reduction in maximum ED vasodilatation was
observed in the AVF forearm when comparing the preoperative and
postoperative values.  In the non AVF forearm (systemically), a significant
reduction in maximum response to NED was observed postoperatively
compared to their preoperative values.
We suggested that the changes in AVF forearm could well be explained by
changes in the local shear stress inducing secondary changes in endothelial
function as a result of the AVF formation. Furthermore, systemically, the
described changes in haemodynamics and arterial stiffness could well
contribute to the described changes in microcirculation function in the non
AVF arm.
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Majority of patients with CKD have already on going endothelial dysfunction
secondary to other metabolic and biochemical abnormalities, even prior to
AVF formation.  This change in endothelial function secondary to the AVF
formation is an important observation due to the previous studies linking
abnormal endothelial function with abnormalities of other vital circulation. One
interesting negative finding was lack of correlation between baseline and
maximum vasodilatation and the likelihood of an AVF formation being
successful or not. However; endothelial dysfunction may well contribute to
further impairment of already diseased peripheral vessels in CKD patients
and may well play an important role in future local vascular complications and
AVF failure. Certainly further prospective studies are required to explore the
relationship between microcirculation and fistula dysfunction.
In conclusion, the results described in this thesis demonstrate that AVF
formation is associated with significant changes in haemodynamics, left
ventricular ejection fraction and arterial stiffness. These changes are
persistent even after AVF maturation.  Associated with these, was a
significant reduction in maximum ED and NED vasodilatation response in the
AVF and non AVF forearm respectively.
The findings of this thesis suggest that the improvement in the
haemodynamic profile and arterial stiffness indices could well contribute to
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improved overall survival of patients who have native AVF s as their primary
and definitive vascular access compared to other vascular accesses types.
9.2 Limitations
This study has a number of limitations. Although this study is the first to
prospectively follow a cohort of patients after their first AVF formation and
extensively investigate the acute postoperative changes in their
haemodynamics and after a reasonable period of maturation, we have not
studied the longer term adaptive changes that might be associated with the
AVF in use.
 Due to low rate of AV graft placement in our centre, this study did not include
any patient with AV graft. It is therefore unrealistic to comment on how the
haemodynamic changes in response to a graft placement. Likewise we did
not have access to a comparable population of well controlled patients within
the low clearance clinic setting who were dialysed with tunnelled venous
catheters.
Other potential limitations to this study include small number of the sample
which is mostly due to the study design of only including patients without prior
exposure to haemodialysis undergoing AVF formation. The small sample size
hindered performing further analysis of the cohort according to their Qa flow
or the type of the fistula constructed.
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Similar to all studies measuring haemodynamics, each study session will be
inevitably limited by its duration. Every care has been taken to recreate
identical situations during each session. Furthermore, individual patient were
studied during the same time of the day and in the same place to avoid
potential external influences on repeated measurements.
The study sample was typical for CKD 4/5 in a hospital based low clearance
setting, and clearly a degree of selection for patients potentially suitable for
HD would occur. The small sample size hindered performing further analysis
of the cohort according to their Qa flow or the type of the fistula constructed.
One of the other study limitations is the use of Doppler ultrasound to measure
the flow in the AVF and the supplying artery. Doppler ultrasound is well
established as a safe, non-invasive, and versatile diagnostic modality and is
widely used to investigate problematic AVF s. However, as with any
ultrasound technique, assessment of flow in the AVF remains subjective. To
minimise these factors, a single operator acquired all Doppler images to
minimise inter-observer variability. This has been further reduced by using a
section of AVF devoid of turbulent flow and as straight as possible. Two
measurements were taken and the average calculated and used for
subsequent analysis. Nevertheless, Doppler ultrasound remains the only
method to measure the flow rate in a fistula which has not been used for
dialysis yet.
Despite all the described limitations, this study increases our understanding of
the acute and longer term physiological changes in cardiovascular structure
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and function associated with constructing an AVF. All of the assumptions
made in the initial choice of the sample size with respect to the primary end
point of change in PWV were met.
Assessing the effect of AVF flow rate on dialysis induced cardiac injury had a
number of significant limitations. It only provides preliminary evidence in a
cross sectional study of patients. Prospective investigation of the effects of
AVF formation and systemic cardiovascular effects are imperative. The
method of measuring Qa is performed during dialysis, and there might be
artefacts from cardiac performance itself. There was however no difference in
blood pressures between the three groups, and all Qa measurements were
made in the first 30 minutes of dialysis to minimise this effect. Dialysis
induced RWMA development does not usually become evident until at least 2
hours into HD197. The ionic dialysance method itself has been correlated well
with ultrasonic saline dilution techniques199, but may have a degree of
variance in the absolute Qa values recorded. Addition of a further non HD
based assessment (MR or ultrasound Doppler) would strengthen this
element. The advantage of the ionic dialysance based method is that it
removes much of the operator dependency of more commonly employed
techniques, and is in general use for access surveillance within our dialysis
unit.
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9.3 Future Work
This thesis describes the acute and longer term consequences of AVF
formation. However; there remain several unanswered questions.
Future studies are required to investigate longer term (> 3months)
consequences of AVF formation. In addition, recording how the AVF
haemodynamics change in response to starting dialysis and how the AVF
flow affects systemic haemodynamics during dialysis is also an interesting
area to study.
Furthermore, the effect of cardiovascular structure and function and different
other haemodynamic variables on the function and survivability of AVF is
another area for further study. In fact, such a study may yield data which
could potentially enable intervention to improve longer term outcome of AVFs.
One of the limitations with our study was the small size of our cohort. A larger
cohort could power the study enabling further statistical analysis to derive
important information such as:
? Logistic regression model to investigate the factors affecting the
success/failure of AVF operation.
? Bigger, more comprehensive regression model to look for the factors
affecting the AVF flow and ∆PWV.
? Sub-classifying the cohort according to the anatomical location of the
placed AVF and/or flow rate in the AVF.
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With regards to the effects on AVF creation on microvasculature and
endothelial function, a number of issues remain. Firstly, at this stage it is not
clear what drives the acute changes observed. Although a model has been
proposed, the pathophysiological mechanisms are still not clear.
Measurement of markers of endothelial functions such as NO, ADMA and
SDMA can assist in understanding these changes further.  We are currently
collaborating with certain centres in Europe to achieve this.
Secondly, it is unknown how the observed changes are maintained beyond
the acute postoperative phase and if these changes affect the fistula survival
and cardiovascular outcome in this group of patients. Certainly this is an area
for further research in the future.
A longitudinal study to assess the effect of AVF flow on dialysis induced
myocardial dysfunction is necessary to ascertain the findings in our cross
sectional observation. In fact, our centre is currently running a study using
cardiac magnetic resonance imaging to establish the longer term
consequences of different variables on myocardial stunning and possible
interventions to improve outcome in haemodialysis population.
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10 Abbreviations
ACEi Angiotensin-II converting enzyme inhibitor
Ach Acetylcholine
ADMA Asymmetrical dimethyl Arginine
AIx Aortic augmentation index
ARB Angiotensin receptor blocker
AVG Arteriovenous grafts
AVF Arteriovenous fistula
BP Blood pressure
BIA Bioimpedance analysis
BMI Body mass index
BNP Brain nitriuretic peptide
BRS Baroreflex sensitivity
CKD Chronic kidney diseases
CF-PWV Carotid femoral pulse wave velocity
CI Cardiac index
CO Cardiac output
CRP C-reactive protein
CrCl Creatinine clearance
CVC Central venous catheter
cTNT Cardiac troponin-T
DBP Diastolic blood pressure
ED Endothelial dependant
EF Ejection Fraction
eGFR Estimated glomerular filtration rate
ESRF End stage renal failure
Hcy Homocystiene
IHD Ischaemic heart disease
KDOQI Kidney Disease Outcomes Quality Initiative
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HDL High density lipoprotein
HR Heart rate
LDI Laser Doppler imaging
LDL Low density lipoprotein
LV Left ventricle
LVH Left ventricular hypertrophy
NED Non endothelial dependant
NO Nitric oxide
PWV Pulse wave velocity
Qa fistula blood flow rate
RIPC Remote ischaemic preconditioning
RRT Renal replacement therapy
SBP Systolic blood pressure
SD Standard deviation
SDMA Symmetrical Dimethyl Arginine
SNP Sodium nitroprusside
SV Stroke volume
TBW Total body water
TG Triglyceride
TPR Total peripheral resistance
UK United Kingdom
US United States
USRDS United States Renal Data System
USS Ultrasound
VC Vascular calcification
VLDL Very low density lipoprotein
WHO World health organisation
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